JS1-5 Circumvention of TKI resistance with HDAC inhibitors in lung cancer (Englisch)
- Neue Suche nach: Yano, S.
- Neue Suche nach: Yano, S.
In:
ANNALS OF ONCOLOGY
;
26
;
vii19-vii19
;
2015
-
ISSN:
- Aufsatz (Zeitschrift) / Print
-
Titel:JS1-5 Circumvention of TKI resistance with HDAC inhibitors in lung cancer
-
Beteiligte:Yano, S. ( Autor:in )
-
Erschienen in:ANNALS OF ONCOLOGY ; 26 ; vii19-vii19
-
Verlag:
- Neue Suche nach: OXFORD UNIVERSITY PRESS
-
Erscheinungsdatum:01.01.2015
-
Format / Umfang:vii19-vii19
-
ISSN:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Print
-
Sprache:Englisch
- Neue Suche nach: 616.992
- Weitere Informationen zu Dewey Decimal Classification
-
Klassifikation:
DDC: 616.992 -
Datenquelle:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Inhaltsverzeichnis – Band 26
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 1
-
thanks to referees 2014| 2015
- 7
-
Phase I trials in oncology: a new era has startedPostel-Vinay, S. / Soria, J. C. et al. | 2015
- 9
-
Challenges in combining novel molecularly targeted agents in cancer medicineYap, T. A. et al. | 2015
- 11
-
Pushing the boundaries of somatic copy-number variation detection: advances and challengesSathirapongsasuti, J. F. et al. | 2015
- 13
-
Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trialsSorich, M. J. / Wiese, M. D. / Rowland, A. / Kichenadasse, G. / McKinnon, R. A. / Karapetis, C. S. et al. | 2015
- 21
-
Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)†Maschmeyer, G. / Carratalà, J. / Buchheidt, D. / Hamprecht, A. / Heussel, C. P. / Kahl, C. / Lorenz, J. / Neumann, S. / Rieger, C. / Ruhnke, M. et al. | 2015
- 33
-
Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevanceKhoja, L. / Lorigan, P. / Dive, C. / Keilholz, U. / Fusi, A. et al. | 2015
- 40
-
Immune biomarkers of anti-EGFR monoclonal antibody therapyTrivedi, S. / Concha-Benavente, F. / Srivastava, R. M. / Jie, H. B. / Gibson, S. P. / Schmitt, N. C. / Ferris, R. L. et al. | 2015
- 47
-
Estimates of benefits and harms of prophylactic use of aspirin in the general populationCuzick, J. / Thorat, M. A. / Bosetti, C. / Brown, P. H. / Burn, J. / Cook, N. R. / Ford, L. G. / Jacobs, E. J. / Jankowski, J. A. / La Vecchia, C. et al. | 2015
- 58
-
A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumorsTolcher, A. W. / Bendell, J. C. / Papadopoulos, K. P. / Burris, H. A. / Patnaik, A. / Jones, S. F. / Rasco, D. / Cox, D. S. / Durante, M. / Bellew, K. M. et al. | 2015
- 64
-
Sequenza: allele-specific copy number and mutation profiles from tumor sequencing dataFavero, F. / Joshi, T. / Marquard, A. M. / Birkbak, N. J. / Krzystanek, M. / Li, Q. / Szallasi, Z. / Eklund, A. C. et al. | 2015
- 70
-
Chemotherapy benefit for ‘ER-positive’ breast cancer and contamination of Nonluminal subtypes—waiting for TAILORx and RxPONDERSun, Z. / Prat, A. / Cheang, M. C. / Gelber, R. D. / Perou, C. M. et al. | 2015
- 75
-
Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapySheri, A. / Smith, I. E. / Johnston, S. R. / A'Hern, R. / Nerurkar, A. / Jones, R. L. / Hills, M. / Detre, S. / Pinder, S. E. / Symmans, W. F. et al. | 2015
- 81
-
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survivalTobin, N. P. / Harrell, J. C. / Lövrot, J. / Egyhazi Brage, S. / Frostvik Stolt, M. / Carlsson, L. / Einbeigi, Z. / Linderholm, B. / Loman, N. / Malmberg, M. et al. | 2015
- 89
-
Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancerCao, K. I. / Lebas, N. / Gerber, S. / Levy, C. / Le Scodan, R. / Bourgier, C. / Pierga, J. Y. / Gobillion, A. / Savignoni, A. / Kirova, Y. M. et al. | 2015
- 95
-
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy†Lindner, J. L. / Loibl, S. / Denkert, C. / Ataseven, B. / Fasching, P. A. / Pfitzner, B. M. / Gerber, B. / Gade, S. / Darb-Esfahani, S. / Sinn, B. V. et al. | 2015
- 101
-
Obesity and the outcome of young breast cancer patients in the UK: the POSH studyCopson, E. R. / Cutress, R. I. / Maishman, T. / Eccles, B. K. / Gerty, S. / Stanton, L. / Altman, D. G. / Durcan, L. / Wong, C. / Simmonds, P. D. et al. | 2015
- 113
-
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA†Krop, I. E. / Lin, N. U. / Blackwell, K. / Guardino, E. / Huober, J. / Lu, M. / Miles, D. / Samant, M. / Welslau, M. / Diéras, V. et al. | 2015
- 120
-
Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancerTreilleux, I. / Arnedos, M. / Cropet, C. / Wang, Q. / Ferrero, J. M. / Abadie-Lacourtoisie, S. / Levy, C. / Legouffe, E. / Lortholary, A. / Pujade-Lauraine, E. et al. | 2015
- 126
-
Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial†Klingbiel, D. / Saridaki, Z. / Roth, A. D. / Bosman, F. T. / Delorenzi, M. / Tejpar, S. et al. | 2015
- 132
-
Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trialÉlez, E. / Kocáková, I. / Höhler, T. / Martens, U. M. / Bokemeyer, C. / Van Cutsem, E. / Melichar, B. / Smakal, M. / Csőszi, T. / Topuzov, E. et al. | 2015
- 141
-
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancerYamada, Y. / Higuchi, K. / Nishikawa, K. / Gotoh, M. / Fuse, N. / Sugimoto, N. / Nishina, T. / Amagai, K. / Chin, K. / Niwa, Y. et al. | 2015
- 149
-
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II studyVan Cutsem, E. / Boni, C. / Tabernero, J. / Massuti, B. / Middleton, G. / Dane, F. / Reichardt, P. / Pimentel, F. L. / Cohn, A. / Follana, P. et al. | 2015
- 156
-
Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growthKobayashi, Y. / Mitsudomi, T. / Sakao, Y. / Yatabe, Y. et al. | 2015
- 161
-
Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencingSun, J. M. / Choi, Y. L. / Ji, J. H. / Ahn, J. S. / Kim, K. M. / Han, J. / Ahn, M. J. / Park, K. et al. | 2015
- 167
-
High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study†Necchi, A. / Mariani, L. / Di Nicola, M. / Lo Vullo, S. / Nicolai, N. / Giannatempo, P. / Raggi, D. / Farè, E. / Magni, M. / Piva, L. et al. | 2015
- 173
-
Renal impairment and late toxicity in germ-cell cancer survivorsLauritsen, J. / Mortensen, M. S. / Kier, M. G. / Christensen, I. J. / Agerbaek, M. / Gupta, R. / Daugaard, G. et al. | 2015
- 179
-
Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trialCella, D. / Ivanescu, C. / Holmstrom, S. / Bui, C. N. / Spalding, J. / Fizazi, K. et al. | 2015
- 185
-
Differences among young adults, adults and elderly chronic myeloid leukemia patientsCastagnetti, F. / Gugliotta, G. / Baccarani, M. / Breccia, M. / Specchia, G. / Levato, L. / Abruzzese, E. / Rossi, G. / Iurlo, A. / Martino, B. et al. | 2015
- 193
-
90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomasBouabdallah, K. / Furst, S. / Asselineau, J. / Chevalier, P. / Tournilhac, O. / Ceballos, P. / Vigouroux, S. / Tabrizi, R. / Doussau, A. / Bouabdallah, R. et al. | 2015
- 198
-
Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decadesDas, L. C. / Karrison, T. G. / Witt, M. E. / Muller, C. / Stenson, K. / Blair, E. A. / Cohen, E. E. / Seiwert, T. Y. / Haraf, D. J. / Vokes, E. E. et al. | 2015
- 205
-
A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinomaChen, Y. P. / Wang, Z. X. / Chen, L. / Liu, X. / Tang, L. L. / Mao, Y. P. / Li, W. F. / Lin, A. H. / Sun, Y. / Ma, J. et al. | 2015
- 211
-
Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agencyMaeda, H. / Kurokawa, T. et al. | 2015
- 217
-
Nutritional assessment in overweight and obese patients with metastatic cancer: does it make sense?Gioulbasanis, I. / Martin, L. / Baracos, V. E. / Thézénas, S. / Koinis, F. / Senesse, P. et al. | 2015
- 221
-
Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative Observational Study prospective cohort†Wang, A. / Kubo, J. / Luo, J. / Desai, M. / Hedlin, H. / Henderson, M. / Chlebowski, R. / Tindle, H. / Chen, C. / Gomez, S. et al. | 2015
- 231
-
Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapyBylicki, O. / Gan, H. K. / Joly, F. / Maillet, D. / You, B. / Péron, J. et al. | 2015
- 238
-
Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK ‘borderline’-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategiesIlie, M. I. / Bence, C. / Hofman, V. / Long-Mira, E. / Butori, C. / Bouhlel, L. / Lalvée, S. / Mouroux, J. / Poudenx, M. / Otto, J. et al. | 2015
- 245
-
Is fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage III colon cancer?Abali, H. / Yavuz, S. / Calıkusu, Z. / Seyrek, E. et al. | 2015
- 245
-
Reply to the Letter to the Editor ‘Is fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage III colon cancer?’ by Abali et al.Sugihara, K. / Yoshida, M. / Ishiguro, M. et al. | 2015
- 246
-
A novel germline mutation of PDGFR-β might be associated with clinical response of colorectal cancer to regorafenibRechsteiner, M. / Wild, P. / Kiessling, M. K. / Bohnert, A. / Zhong, Q. / Stahel, R. A. / Moch, H. / Curioni-Fontecedro, A. et al. | 2015
- 248
-
Pharmacokinetic interaction involving fenofibrate and everolimusMir, O. / Poinsignon, V. / Arnedos, M. / Delaloge, S. / Paci, A. et al. | 2015
- 249
-
Reply to the letter to the editor ‘Measured and estimated glomerular filtration rate for carboplatin dose calculation’ by Cathomas et al.Bertelli, G. / Quinton, A. E. / Lewis, P. D. / Ali, P. / Morgan, C. et al. | 2015
- 250
-
Reply to the letters to the editor ‘Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma’ by Diwakar et al.Schilling, B. / Sondermann, W. / Griewank, K. G. / Livingstone, E. / Zimmer, L. / Hillen, U. / Schadendorf, D. et al. | 2015
- 251
-
Reply to the letters to the editor ‘Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma’ by Schilling et al.Davar, D. / Choi, T. / Kirkwood, J. M. et al. | 2015
- 252
-
Letter to the editor concerning ‘Elevated serum antibodies against insulin-like growth factor-binding protein-2 allow detecting early-stage cancers: evidences from glioma and colorectal carcinoma studies’Hassan, W. A. / Bjerre, M. / Hjortebjerg, R. / Magnusson, N. E. / Ramshanker, N. / Frystyk, J. et al. | 2015
- 254
-
P–0271 Concurrent oral UFT and pelvic irradiation as neoadjuvant chemoradiation for operable rectal cancer: a phase II studyHelmy, S. / Abo-Zeid, A. A. / Gado, N. M. / Salman, M. I. / Bassyoni, M. M. / Abd Al Samee, A. / Salem, D. A. et al. | 2015
- 259
-
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014Salgado, R. / Denkert, C. / Demaria, S. / Sirtaine, N. / Klauschen, F. / Pruneri, G. / Wienert, S. / Van den Eynden, G. / Baehner, F. L. / Penault-Llorca, F. et al. | 2015
- 272
-
Cardiorespiratory fitness as predictor of cancer mortality: a systematic review and meta-analysisSchmid, D. / Leitzmann, M. F. et al. | 2015
- 278
-
Concurrent systemic therapy with radiotherapy for the treatment of poor-risk patients with unresectable stage III non-small-cell lung cancer: a review of the literatureCardenal, F. / Nadal, E. / Jové, M. / Faivre-Finn, C. et al. | 2015
- 288
-
Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†Decoster, L. / Van Puyvelde, K. / Mohile, S. / Wedding, U. / Basso, U. / Colloca, G. / Rostoft, S. / Overcash, J. / Wildiers, H. / Steer, C. et al. | 2015
- 300
-
Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paperCasali, P. G. / Bruzzi, P. / Bogaerts, J. / Blay, J. Y. et al. | 2015
- 307
-
Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapyMontagna, E. / Bagnardi, V. / Viale, G. / Rotmensz, N. / Sporchia, A. / Cancello, G. / Balduzzi, A. / Galimberti, V. / Veronesi, P. / Luini, A. et al. | 2015
- 313
-
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12Gnant, M. / Mlineritsch, B. / Stoeger, H. / Luschin-Ebengreuth, G. / Knauer, M. / Moik, M. / Jakesz, R. / Seifert, M. / Taucher, S. / Bjelic-Radisic, V. et al. | 2015
- 320
-
Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH studyJackisch, C. / Kim, S. B. / Semiglazov, V. / Melichar, B. / Pivot, X. / Hillenbach, C. / Stroyakovskiy, D. / Lum, B. L. / Elliott, R. / Weber, H. A. et al. | 2015
- 325
-
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 studyBonnefoi, H. / Jacot, W. / Saghatchian, M. / Moldovan, C. / Venat-Bouvet, L. / Zaman, K. / Matos, E. / Petit, T. / Bodmer, A. / Quenel-Tueux, N. et al. | 2015
- 332
-
Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancerSunakawa, Y. / Stremitzer, S. / Cao, S. / Zhang, W. / Yang, D. / Wakatsuki, T. / Ning, Y. / Yamauchi, S. / Stintzing, S. / Sebio, A. et al. | 2015
- 340
-
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trialHebbar, M. / Chibaudel, B. / André, T. / Mineur, L. / Smith, D. / Louvet, C. / Dutel, J. L. / Ychou, M. / Legoux, J. L. / Mabro, M. et al. | 2015
- 368
-
Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal eventsSmith, M. R. / Coleman, R. E. / Klotz, L. / Pittman, K. / Milecki, P. / Ng, S. / Chi, K. N. / Balakumaran, A. / Wei, R. / Wang, H. et al. | 2015
- 374
-
Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapyVidal, A. D. / Thalmann, G. N. / Karamitopoulou-Diamantis, E. / Fey, M. F. / Studer, U. E. et al. | 2015
- 407
-
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment†Whelan, J. S. / Bielack, S. S. / Marina, N. / Smeland, S. / Jovic, G. / Hook, J. M. / Krailo, M. / Anninga, J. / Butterfass-Bahloul, T. / Böhling, T. et al. | 2015
- 415
-
Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trialMenzies, A. M. / Ashworth, M. T. / Swann, S. / Kefford, R. F. / Flaherty, K. / Weber, J. / Infante, J. R. / Kim, K. B. / Gonzalez, R. / Hamid, O. et al. | 2015
- 422
-
A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trialsDoussau, A. / Thiébaut, R. / Geoerger, B. / Schöffski, P. / Floquet, A. / Le Deley, M. C. / Mathoulin-Pélissier, S. / Rizzo, E. / Fumoleau, P. / Le Tourneau, C. et al. | 2015
- 428
-
Cytokine profile determined by data-mining analysis set into clusters of non-small-cell lung cancer patients according to prognosisBarrera, L. / Montes-Servín, E. / Barrera, A. / Ramírez-Tirado, L. A. / Salinas-Parra, F. / Bañales-Méndez, J. L. / Sandoval-Ríos, M. / Arrieta, . et al. | 2015
- 436
-
T-DM1-related telangiectasias: a potential role in secondary bleeding eventsSibaud, V. / Vigarios, E. / Combemale, P. / Lamant, L. / Lacouture, M. E. / Lacaze, J. L. / Dalenc, F. / Delord, J. P. et al. | 2015
- 437
-
Withdrawal of hormone replacement therapy might affect multigene signature results in early luminal breast cancerNeven, P. / Jongen, L. / Van Asten, K. / Berteloot, P. / Floris, G. / Wildiers, H. et al. | 2015
- 439
-
Can obesity be an advantage for febrile neutropenia?Alkan, A. / Bir, K. / Utkan, G. et al. | 2015
- 440
-
The obesity and cancer linkBifulco, M. et al. | 2015
- 441
-
The harms of low-dose aspirin prophylaxis are overstatedElwood, P. / Morgan, G. et al. | 2015
- 442
-
Reply to the letter to the editor ‘The harms of low-dose aspirin prophylaxis are overstated’ by P. Elwood and G. MorganThorat, M. A. / Cuzick, J. et al. | 2015
- 443
-
Albumin to globulin ratio, a predictor or a misleader?Alkan, A. / Köksoy, E. B. / Utkan, G. et al. | 2015
- 445
-
Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumorsSoria, J. C. / DeBraud, F. / Bahleda, R. / Adamo, B. / Andre, F. / Dienstmann, R. / Delmonte, A. / Cereda, R. / Isaacson, J. / Litten, J. et al. | 2015
- 445
-
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features| 2015
- 447
-
The failure of figitumumab: the danger of taking shortcuts in drug developmentWest, H. et al. | 2015
- 448
-
Nit-Picking around second line in EGFRwt NSCLC: just an academic effortLandi, L. / Cappuzzo, F. et al. | 2015
- 463
-
Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013Papamichael, D. / Audisio, R. A. / Glimelius, B. / de Gramont, A. / Glynne-Jones, R. / Haller, D. / K�hne, C. H. / Rostoft, S. / Lemmens, V. / Mitry, E. et al. | 2015
- 497
-
Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancerScagliotti, G. V. / Bondarenko, I. / Blackhall, F. / Barlesi, F. / Hsia, T. C. / Jassem, J. / Milanowski, J. / Popat, S. / Sanchez-Torres, J. M. / Novello, S. et al. | 2015
- 504
-
Randomized phase III trial of prophylactic cranial irradiation versus observation in patients with fully resected stage IIIAN2 nonsmall-cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapyLi, N. / Zeng, Z. F. / Wang, S. Y. / Ou, W. / Ye, X. / Li, J. / He, X. H. / Zhang, B. B. / Yang, H. / Sun, H. B. et al. | 2015
- 510
-
Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patientsMostert, B. / Sieuwerts, A. M. / Kraan, J. / Bolt-de Vries, J. / van der Spoel, P. / van Galen, A. / Peeters, D. J. / Dirix, L. Y. / Seynaeve, C. M. / Jager, A. et al. | 2015
- 517
-
Breast cancer genetic risk profile is differentially associated with interval and screen-detected breast cancersLi, J. / Holm, J. / Bergh, J. / Eriksson, M. / Darabi, H. / Lindstr�m, L. S. / T�rnberg, S. / Hall, P. / Czene, K. et al. | 2015
- 523
-
Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancerWang, C. / Zhang, J. / Wang, Y. / Ouyang, T. / Li, J. / Wang, T. / Fan, Z. / Fan, T. / Lin, B. / Xie, Y. et al. | 2015
- 529
-
Patterns of practice of regional nodal irradiation in breast cancer: results of the European Organization for Research and Treatment of Cancer (EORTC) NOdal Radiotherapy (NORA) surveyBelkacemi, Y. / Kaidar-Person, O. / Poortmans, P. / Ozsahin, M. / Valli, M. C. / Russell, N. / Kunkler, I. / Hermans, J. / Kuten, A. / van Tienhoven, G. et al. | 2015
- 535
-
Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancerSotelo, M. J. / Sastre, J. / Maestro, M. L. / Veganzones, S. / Vi�itez, J. M. / Alonso, V. / Gr�valos, C. / Escudero, P. / Vera, R. / Aranda, E. et al. | 2015
- 542
-
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh studySantoro, A. / Gebbia, V. / Pressiani, T. / Testa, A. / Personeni, N. / Arrivas Bajardi, E. / Foa, P. / Buonadonna, A. / Bencardino, K. / Barone, C. et al. | 2015
- 548
-
EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity?Hong, J. Y. / Yoon, D. H. / Suh, C. / Huh, J. / Do, I. G. / Sohn, I. / Jo, J. / Jung, S. H. / Hong, M. E. / Yoon, H. et al. | 2015
- 556
-
A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancerJimeno, A. / Shirai, K. / Choi, M. / Laskin, J. / Kochenderfer, M. / Spira, A. / Cline-Burkhardt, V. / Winquist, E. / Hausman, D. / Walker, L. et al. | 2015
- 561
-
TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO)Gr�nwald, V. / Keilholz, U. / Boehm, A. / Guntinas-Lichius, O. / Hennemann, B. / Schmoll, H. J. / Ivanyi, P. / Abbas, M. / Lehmann, U. / Koch, A. et al. | 2015
- 567
-
Synovial sarcoma in children and adolescents: the European Pediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005)Ferrari, A. / De Salvo, G. L. / Brennan, B. / van Noesel, M. M. / De Paoli, A. / Casanova, M. / Francotte, N. / Kelsey, A. / Alaggio, R. / Oberlin, O. et al. | 2015
- 573
-
A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survivalUgurel, S. / Loquai, C. / K�hler, K. / Hassel, J. / Berking, C. / Zimmer, L. / Haubitz, I. / Satzger, I. / M�ller-Brenne, T. / Mikhaimer, N. C. et al. | 2015
- 582
-
Impact of centralization on aCGH-based genomic profiles for precision medicine in oncologyCommo, F. / Fert�, C. / Soria, J. C. / Friend, S. H. / Andr�, F. / Guinney, J. et al. | 2015
- 589
-
Socioeconomic disparities in survival from childhood leukemia in the United States and globally: a meta-analysisPetridou, E. T. / Sergentanis, T. N. / Perlepe, C. / Papathoma, P. / Tsilimidos, G. / Kontogeorgi, E. / Kourti, M. / Baka, M. / Moschovi, M. / Polychronopoulou, S. et al. | 2015
- 598
-
Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II studySch�ffski, P. / Besse, B. / Gauler, T. / de Jonge, M. J. / Scambia, G. / Santoro, A. / Davite, C. / Jannuzzo, M. G. / Petroccione, A. / Delord, J. P. et al. | 2015
- 608
-
Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphomaa long-term follow-up studyKasenda, B. / Schorb, E. / Fritsch, K. / Finke, J. / Illerhaus, G. et al. | 2015
- 613
-
Different adjuvant chemotherapy regimens in older breast cancer patients?Wildiers, H. / Brain, E. et al. | 2015
- 615
-
Postoperative surveillance in nonmetastatic colorectal cancer patients: yes, butCastells, A. et al. | 2015
- 617
-
Adjuvant chemotherapy for rectal cancer after preoperative radiation or chemoradiation: One size does not fit allCervantes, A. / Glynne-Jones, R. et al. | 2015
- 620
-
Contralateral biopsies in patients with testicular germ-cell tumournuisance or new sense?Dieckmann, K. P. et al. | 2015
- 622
-
Neutrophil to lymphocyte ratio: another drop in the ocean of CRPC biomakers?Castro, E. / Lozano, R. / Olmos, D. et al. | 2015
- 624
-
A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stageFindlay, J. M. / Middleton, M. R. / Tomlinson, I. et al. | 2015
- 644
-
Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysisPita-Fern�ndez, S. / Alhayek-A�, M. / Gonz�lez-Mart�n, C. / L�pez-Calvi�o, B. / Seoane-Pillado, T. / P�rtega-D�az, S. et al. | 2015
- 657
-
Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomesGiannatempo, P. / Greco, T. / Mariani, L. / Nicolai, N. / Tana, S. / Far�, E. / Raggi, D. / Piva, L. / Catanzaro, M. / Biasoni, D. et al. | 2015
- 669
-
Designs of drug-combination phase I trials in oncology: a systematic review of the literatureRiviere, M. K. / Le Tourneau, C. / Paoletti, X. / Dubois, F. / Zohar, S. et al. | 2015
- 675
-
Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trialPerrone, F. / Nuzzo, F. / Di Rella, F. / Gravina, A. / Iodice, G. / Labonia, V. / Landi, G. / Pacilio, C. / Rossi, E. / De Laurentiis, M. et al. | 2015
- 682
-
Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situCurigliano, G. / Disalvatore, D. / Esposito, A. / Pruneri, G. / Lazzeroni, M. / Guerrieri-Gonzaga, A. / Luini, A. / Orecchia, R. / Goldhirsch, A. / Rotmensz, N. et al. | 2015
- 688
-
Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysisAapro, M. / Moebus, V. / Nitz, U. / O'Shaughnessy, J. / Pronzato, P. / Untch, M. / Tomita, D. / Bohac, C. / Leyland-Jones, B. et al. | 2015
- 696
-
Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trialBreugom, A. J. / van Gijn, W. / Muller, E. W. / Berglund, . / van den Broek, C. B. / Fokstuen, T. / Gelderblom, H. / Kapiteijn, E. / Leer, J. W. / Marijnen, C. A. et al. | 2015
- 702
-
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trialGruenberger, T. / Bridgewater, J. / Chau, I. / Garc�a Alfonso, P. / Rivoire, M. / Mudan, S. / Lasserre, S. / Hermann, F. / Waterkamp, D. / Adam, R. et al. | 2015
- 709
-
Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)Koeberle, D. / Betticher, D. C. / von Moos, R. / Dietrich, D. / Brauchli, P. / Baertschi, D. / Matter, K. / Winterhalder, R. / Borner, M. / Anchisi, S. et al. | 2015
- 715
-
Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trialsHaller, D. G. / O'Connell, M. J. / Cartwright, T. H. / Twelves, C. J. / McKenna, E. F. / Sun, W. / Saif, M. W. / Lee, S. / Yothers, G. / Schmoll, H. J. et al. | 2015
- 724
-
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trialMasi, G. / Salvatore, L. / Boni, L. / Loupakis, F. / Cremolini, C. / Fornaro, L. / Schirripa, M. / Cupini, S. / Barbara, C. / Safina, V. et al. | 2015
- 731
-
Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatmentMorelli, M. P. / Overman, M. J. / Dasari, A. / Kazmi, S. M. / Mazard, T. / Vilar, E. / Morris, V. K. / Lee, M. S. / Herron, D. / Eng, C. et al. | 2015
- 737
-
Screening for carcinoma in situ in the contralateral testicle in patients with testicular cancer: a population-based studyKier, M. G. / Lauritsen, J. / Almstrup, K. / Mortensen, M. S. / Toft, B. G. / Rajpert-De Meyts, E. / Skakkebaek, N. E. / R�rth, M. / von der Maase, H. / Agerbaek, M. et al. | 2015
- 743
-
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trialsvan Soest, R. J. / Templeton, A. J. / Vera-Badillo, F. E. / Mercier, F. / Sonpavde, G. / Amir, E. / Tombal, B. / Rosenthal, M. / Eisenberger, M. A. / Tannock, I. F. et al. | 2015
- 750
-
Baseline neutrophillymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid useLorente, D. / Mateo, J. / Templeton, A. J. / Zafeiriou, Z. / Bianchini, D. / Ferraldeschi, R. / Bahl, A. / Shen, L. / Su, Z. / Sartor, O. et al. | 2015
- 756
-
Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomesKote-Jarai, Z. / Mikropoulos, C. / Leongamornlert, D. A. / Dadaev, T. / Tymrakiewicz, M. / Saunders, E. J. / Jones, M. / Jugurnauth-Little, S. / Govindasami, K. / Guy, M. et al. | 2015
- 762
-
A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancerLim, S. H. / Lee, J. Y. / Lee, M. Y. / Kim, H. S. / Lee, J. / Sun, J. M. / Ahn, J. S. / Um, S. W. / Kim, H. / Kim, B. S. et al. | 2015
- 768
-
Adjuvant chemotherapy for elderly patients with stage I non-small-cell lung cancer ?4 cm in size: an SEERMedicare analysisMalhotra, J. / Mhango, G. / Gomez, J. E. / Smith, C. / Galsky, M. D. / Strauss, G. M. / Wisnivesky, J. P. et al. | 2015
- 774
-
Utility of 18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphomaHorwitz, S. / Coiffier, B. / Foss, F. / Prince, H. M. / Sokol, L. / Greenwood, M. / Caballero, D. / Morschhauser, F. / Pinter-Brown, L. / Iyer, S. P. et al. | 2015
- 779
-
European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?Malvezzi, M. / Bertuccio, P. / Rosso, T. / Rota, M. / Levi, F. / La Vecchia, C. / Negri, E. et al. | 2015
- 787
-
Low-dose aspirin use and the risk of ovarian cancer in DenmarkBaandrup, L. / Kjaer, S. K. / Olsen, J. H. / Dehlendorff, C. / Friis, S. et al. | 2015
- 793
-
Expression of estrogen receptors in non-malignant mammary tissue modifies the association between insulin-like growth factor 1 and breast cancer riskSamoli, E. / Lagiou, A. / Zourna, P. / Barbouni, A. / Georgila, C. / Tsikkinis, A. / Vassilarou, D. / Minaki, P. / Sfikas, C. / Spanos, E. et al. | 2015
- 798
-
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II studyDi Giacomo, A. M. / Ascierto, P. A. / Queirolo, P. / Pilla, L. / Ridolfi, R. / Santinami, M. / Testori, A. / Simeone, E. / Guidoboni, M. / Maurichi, A. et al. | 2015
- 804
-
Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancerBendell, J. / O'Reilly, E. M. / Middleton, M. R. / Chau, I. / Hochster, H. / Fielding, A. / Burke, W. / Burris, H. et al. | 2015
- 812
-
Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinomaBellmunt, J. / Mullane, S. A. / Werner, L. / Fay, A. P. / Callea, M. / Leow, J. J. / Taplin, M. E. / Choueiri, T. K. / Hodi, F. S. / Freeman, G. J. et al. | 2015
- 818
-
Reply to the letter to the editor Surrogate end points for overall survival. Festina lente (more haste, less speed) by BraillonMaeda, H. / Kurokawa, T. et al. | 2015
- 818
-
Surrogate end points for overall survival. Festina lente (more haste, less speed)Braillon, A. et al. | 2015
- 819
-
Atypical femur fractures associated with use of bisphosphonates and denosumabFarooki, A. / Fornier, M. / Boland, P. et al. | 2015
- 820
-
Reply to the letter to the editor Albumin to globulin ratio, a predictor or a misleader? by Alkan et al.Suh, B. / Park, S. / Shin, D. W. et al. | 2015
- 821
-
Obesity and cancer: links with survival differ from those with incidenceRenehan, A. G. et al. | 2015
- 822
-
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset| 2015
- 827
-
Adapting the drivers to the road: a new strategy for cancer evolution?Touat, M. / Dhermain, F. / André, F. / Sanson, M. et al. | 2015
- 829
-
An ESMO-EORTC position paper on the EU clinical trials regulation and EMA's transparency policy: making European research more competitive againDittrich, C. / Negrouk, A. / Casali, P. G. et al. | 2015
- 833
-
Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancerOldenburg, J. / Aparicio, J. / Beyer, J. / Cohn-Cedermark, G. / Cullen, M. / Gilligan, T. / De Giorgi, U. / De Santis, M. / de Wit, R. / Fosså, S. D. et al. | 2015
- 838
-
Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumorsSerpico, D. / Trama, A. / Haspinger, E. R. / Agustoni, F. / Botta, L. / Berardi, R. / Palmieri, G. / Zucali, P. / Gallucci, R. / Broggini, M. et al. | 2015
- 848
-
Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysisLouie, K. S. / Seigneurin, A. / Cathcart, P. / Sasieni, P. et al. | 2015
- 865
-
Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†Bellera, C. A. / Penel, N. / Ouali, M. / Bonvalot, S. / Casali, P. G. / Nielsen, O. S. / Delannes, M. / Litière, S. / Bonnetain, F. / Dabakuyo, T. S. et al. | 2015
- 873
-
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†Gourgou-Bourgade, S. / Cameron, D. / Poortmans, P. / Asselain, B. / Azria, D. / Cardoso, F. / A'Hern, R. / Bliss, J. / Bogaerts, J. / Bonnefoi, H. et al. | 2015
- 880
-
Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosomeFavero, F. / McGranahan, N. / Salm, M. / Birkbak, N. J. / Sanborn, J. Z. / Benz, S. C. / Becq, J. / Peden, J. F. / Kingsbury, Z. / Grocok, R. J. et al. | 2015
- 888
-
Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902Sugawara, S. / Oizumi, S. / Minato, K. / Harada, T. / Inoue, A. / Fujita, Y. / Maemondo, M. / Yoshizawa, H. / Ito, K. / Gemma, A. et al. | 2015
- 894
-
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†Blumenschein, G. R. / Smit, E. F. / Planchard, D. / Kim, D. W. / Cadranel, J. / De Pas, T. / Dunphy, F. / Udud, K. / Ahn, M. J. / Hanna, N. H. et al. | 2015
- 902
-
Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosisJanssen-Heijnen, M. L. / van Erning, F. N. / De Ruysscher, D. K. / Coebergh, J. W. / Groen, H. J. et al. | 2015
- 908
-
Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†Pujol, J. L. / Lavole, A. / Quoix, E. / Molinier, O. / Souquet, P. J. / Barlesi, F. / Le Caer, H. / Moro-Sibilot, D. / Fournel, P. / Oster, J. P. et al. | 2015
- 914
-
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study†Monk, B. J. / Ghatage, P. / Parekh, T. / Henitz, E. / Knoblauch, R. / Matos-Pita, A. S. / Nieto, A. / Park, Y. C. / Cheng, P. S. / Li, W. et al. | 2015
- 921
-
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial†Fuchs, C. S. / Azevedo, S. / Okusaka, T. / Van Laethem, J. L. / Lipton, L. R. / Riess, H. / Szczylik, C. / Moore, M. J. / Peeters, M. / Bodoky, G. et al. | 2015
- 928
-
Nomograms to predict survival and the risk for developing local or distant recurrence in patients with rectal cancer treated with optional short-term radiotherapyvan Gijn, W. / van Stiphout, R. G. / van de Velde, C. J. / Valentini, V. / Lammering, G. / Gambacorta, M. A. / Påhlman, L. / Bujko, K. / Lambin, P. et al. | 2015
- 935
-
The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYCTakahashi, Y. / Sheridan, P. / Niida, A. / Sawada, G. / Uchi, R. / Mizuno, H. / Kurashige, J. / Sugimachi, K. / Sasaki, S. / Shimada, Y. et al. | 2015
- 943
-
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancerChen, J. S. / Hsu, C. / Chiang, N. J. / Tsai, C. S. / Tsou, H. H. / Huang, S. F. / Bai, L. Y. / Chang, I. C. / Shiah, H. S. / Ho, C. L. et al. | 2015
- 950
-
Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†Renfro, L. A. / Grothey, A. / Kerr, D. / Haller, D. G. / André, T. / Van Cutsem, E. / Saltz, L. / Labianca, R. / Loprinzi, C. L. / Alberts, S. R. et al. | 2015
- 958
-
Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphomaBarta, S. K. / Samuel, M. S. / Xue, X. / Wang, D. / Lee, J. Y. / Mounier, N. / Ribera, J. M. / Spina, M. / Tirelli, U. / Weiss, R. et al. | 2015
- 966
-
Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL)Chihara, D. / Asano, N. / Ohmachi, K. / Nishikori, M. / Okamoto, M. / Sawa, M. / Sakai, R. / Okoshi, Y. / Tsukamoto, N. / Yakushijin, Y. et al. | 2015
- 973
-
A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas—NCIC-CTG IND 200†Chu, Q. S. / Nielsen, T. O. / Alcindor, T. / Gupta, A. / Endo, M. / Goytain, A. / Xu, H. / Verma, S. / Tozer, R. / Knowling, M. et al. | 2015
- 981
-
Non-intercepted dose errors in prescribing anti-neoplastic treatment: a prospective, comparative cohort studyMattsson, T. O. / Holm, B. / Michelsen, H. / Knudsen, J. L. / Brixen, K. / Herrstedt, J. et al. | 2015
- 987
-
Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastasesde Baère, T. / Aupérin, A. / Deschamps, F. / Chevallier, P. / Gaubert, Y. / Boige, V. / Fonck, M. / Escudier, B. / Palussiére, J. et al. | 2015
- 992
-
Drug–drug interactions in patients treated for cancer: a prospective study on clinical interventions†van Leeuwen, R. W. / Jansman, F. G. / van den Bemt, P. M. / de Man, F. / Piran, F. / Vincenten, I. / Jager, A. / Rijneveld, A. W. / Brugma, J. D. / Mathijssen, R. H. et al. | 2015
- 998
-
Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignanciesWong, A. L. / Soo, R. A. / Tan, D. S. / Lee, S. C. / Lim, J. S. / Marban, P. C. / Kong, L. R. / Lee, Y. J. / Wang, L. Z. / Thuya, W. L. et al. | 2015
- 1005
-
Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer—results of a first-in-man dose-escalation study with a fixed-dose extension phaseIsambert, N. / Delord, J. P. / Soria, J. C. / Hollebecque, A. / Gomez-Roca, C. / Purcea, D. / Rouits, E. / Belli, R. / Fumoleau, P. et al. | 2015
- 1012
-
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradationFu, S. / Hou, M. M. / Naing, A. / Janku, F. / Hess, K. / Zinner, R. / Subbiah, V. / Hong, D. / Wheler, J. / Piha-Paul, S. et al. | 2015
- 1019
-
Molecular phenotypes of DCIS predict overall and invasive recurrence†Williams, K. E. / Barnes, N. L. / Cramer, A. / Johnson, R. / Cheema, K. / Morris, J. / Howe, M. / Bundred, N. J. et al. | 2015
- 1025
-
Long-term effects of inhaled budesonide on screening-detected lung nodulesVeronesi, G. / Lazzeroni, M. / Szabo, E. / Brown, P. H. / DeCensi, A. / Guerrieri-Gonzaga, A. / Bellomi, M. / Radice, D. / Grimaldi, M. C. / Spaggiari, L. et al. | 2015
- 1031
-
Letter to the editor concerning ‘Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis’Carlsson, S. / Assel, M. / Vickers, A. et al. | 2015
- 1031
-
Reply to the letter to the editor ‘Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis’ by Louie et al.Louie, K. S. / Seigneurin, A. / Cathcart, P. / Sasieni, P. et al. | 2015
- 1032
-
Choosing a better end point for trials of bone-protective agentsLeibowitz-Amit, R. / Khoja, L. / Tannock, I. F. / Joshua, A. M. et al. | 2015
- 1033
-
Letter to the editor concerning ‘Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA’Foglietta, J. / Metro, G. / Crinò, L. / Gori, S. et al. | 2015
- 1034
-
How can I validate a nomogram? Show me the modelCollins, G. S. et al. | 2015
- 1035
-
Concomitant EGFR and KRAS mutations in ALK-rearranged lung cancerRossi, G. / Baldi, L. / Barbieri, F. / Bertolini, F. / Tiseo, M. et al. | 2015
- 1036
-
Recent developments in the implementation of novel designs for early-phase combination studiesWages, N. A. / Conaway, M. R. / Slingluff, C. L. / Williams, M. E. / Portell, C. A. / Hwu, P. / Petroni, G. R. et al. | 2015
- 1038
-
A 3′-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma| 2015
- 1041
-
Prioritizing precision medicine for prostate cancerAttard, G. / Beltran, H. et al. | 2015
- 1043
-
Determining the indications for post mastectomy radiotherapy: moving from 20th century clinical staging to 21st century biological criteriaRussell, N. S. / Kunkler, I. H. / van Tienhoven, G. et al. | 2015
- 1045
-
Does interim PET increase the value of ABVD in advanced-stage Hodgkin lymphoma?Gallamini, A. / Kostakoglu, L. et al. | 2015
- 1048
-
Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care?Woolf, D. K. / Padhani, A. R. / Makris, A. et al. | 2015
- 1058
-
Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentaryMorrison, V. A. / Hamlin, P. / Soubeyran, P. / Stauder, R. / Wadhwa, P. / Aapro, M. / Lichtman, S. M. et al. | 2015
- 1069
-
Genetic lesions in diffuse large B-cell lymphomasTestoni, M. / Zucca, E. / Young, K. H. / Bertoni, F. et al. | 2015
- 1081
-
Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive reviewJordan, K. / Jahn, F. / Aapro, M. et al. | 2015
- 1091
-
The prevalence and outcomes of frailty in older cancer patients: a systematic reviewHandforth, C. / Clegg, A. / Young, C. / Simpkins, S. / Seymour, M. T. / Selby, P. J. / Young, J. et al. | 2015
- 1101
-
Visceral adiposity and colorectal adenomas: dose-response meta-analysis of observational studiesKeum, N. / Lee, D. H. / Kim, R. / Greenwood, D. C. / Giovannucci, E. L. et al. | 2015
- 1110
-
Integrative molecular profiling of routine clinical prostate cancer specimensGrasso, C. S. / Cani, A. K. / Hovelson, D. H. / Quist, M. J. / Douville, N. J. / Yadati, V. / Amin, A. M. / Nelson, P. S. / Betz, B. L. / Liu, C. J. et al. | 2015
- 1118
-
EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinomaDavis, I. D. / Long, A. / Yip, S. / Espinoza, D. / Thompson, J. F. / Kichenadasse, G. / Harrison, M. / Lowenthal, R. M. / Pavlakis, N. / Azad, A. et al. | 2015
- 1123
-
First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†Ravaud, A. / Oudard, S. / De Fromont, M. / Chevreau, C. / Gravis, G. / Zanetta, S. / Theodore, C. / Jimenez, M. / Sevin, E. / Laguerre, B. et al. | 2015
- 1128
-
Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinomaIzzedine, H. / Derosa, L. / Le Teuff, G. / Albiges, L. / Escudier, B. et al. | 2015
- 1134
-
Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analysesMitchell, P. / Thatcher, N. / Socinski, M. A. / Wasilewska-Tesluk, E. / Horwood, K. / Szczesna, A. / Martín, C. / Ragulin, Y. / Zukin, M. / Helwig, C. et al. | 2015
- 1142
-
A genetic variation in microRNA target site of KRT81 gene is associated with survival in early-stage non-small-cell lung cancerLee, S. Y. / Choi, J. E. / Jeon, H. S. / Hong, M. J. / Choi, Y. Y. / Kang, H. G. / Yoo, S. S. / Lee, E. B. / Jeong, J. Y. / Lee, W. K. et al. | 2015
- 1149
-
No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population-based studyNordenskjöld, A. E. / Fohlin, H. / Albertsson, P. / Arnesson, L. G. / Chamalidou, C. / Einbeigi, Z. / Holmberg, E. / Nordenskjöld, B. / Karlsson, P. et al. | 2015
- 1155
-
Disseminated tumor cells from the bone marrow of patients with nonmetastatic primary breast cancer are predictive of locoregional relapseHartkopf, A. D. / Wallwiener, M. / Fehm, T. N. / Hahn, M. / Walter, C. B. / Gruber, I. / Brucker, S. Y. / Taran, F. A. et al. | 2015
- 1161
-
Survival in stage I–III breast cancer patients by surgical treatment in a publicly funded health care systemFisher, S. / Gao, H. / Yasui, Y. / Dabbs, K. / Winget, M. et al. | 2015
- 1170
-
Phase II study of interim PET–CT-guided response-adapted therapy in advanced Hodgkin's lymphomaGanesan, P. / Rajendranath, R. / Kannan, K. / Radhakrishnan, V. / Ganesan, T. S. / Udupa, K. / Lakshmipathy, K. M. / Mahajan, V. / Sundersingh, S. / Rajaraman, S. et al. | 2015
- 1175
-
Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomesCheah, C. Y. / Chihara, D. / Romaguera, J. E. / Fowler, N. H. / Seymour, J. F. / Hagemeister, F. B. / Champlin, R. E. / Wang, M. L. et al. | 2015
- 1180
-
A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemiaKorfi, K. / Mandal, A. / Furney, S. J. / Wiseman, D. / Somervaille, T. C. / Marais, R. et al. | 2015
- 1188
-
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord OvestCremolini, C. / Loupakis, F. / Antoniotti, C. / Lonardi, S. / Masi, G. / Salvatore, L. / Cortesi, E. / Tomasello, G. / Spadi, R. / Zaniboni, A. et al. | 2015
- 1194
-
A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancerDeplanque, G. / Demarchi, M. / Hebbar, M. / Flynn, P. / Melichar, B. / Atkins, J. / Nowara, E. / Moyé, L. / Piquemal, D. / Ritter, D. et al. | 2015
- 1201
-
Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trialPassardi, A. / Nanni, O. / Tassinari, D. / Turci, D. / Cavanna, L. / Fontana, A. / Ruscelli, S. / Mucciarini, C. / Lorusso, V. / Ragazzini, A. et al. | 2015
- 1208
-
Postoperative irinotecan in resected stage II–III rectal cancer: final analysis of the French R98 Intergroup trial†Delbaldo, C. / Ychou, M. / Zawadi, A. / Douillard, J. Y. / André, T. / Guerin-Meyer, V. / Rougier, P. / Dupuis, O. / Faroux, R. / Jouhaud, A. et al. | 2015
- 1216
-
Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencingChung, C. H. / Guthrie, V. B. / Masica, D. L. / Tokheim, C. / Kang, H. / Richmon, J. / Agrawal, N. / Fakhry, C. / Quon, H. / Subramaniam, R. M. et al. | 2015
- 1223
-
Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancerDeutsch, E. / Le Péchoux, C. / Faivre, L. / Rivera, S. / Tao, Y. / Pignon, J. P. / Angokai, M. / Bahleda, R. / Deandreis, D. / Angevin, E. et al. | 2015
- 1230
-
Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumorsChiorean, E. G. / Hurwitz, H. I. / Cohen, R. B. / Schwartz, J. D. / Dalal, R. P. / Fox, F. E. / Gao, L. / Sweeney, C. J. et al. | 2015
- 1238
-
Radiosensitization by BRAF inhibitor therapy—mechanism and frequency of toxicity in melanoma patientsHecht, M. / Zimmer, L. / Loquai, C. / Weishaupt, C. / Gutzmer, R. / Schuster, B. / Gleisner, S. / Schulze, B. / Goldinger, S. M. / Berking, C. et al. | 2015
- 1244
-
The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax)Al-Batran, S. E. / Hozaeel, W. / Tauchert, F. K. / Hofheinz, R. D. / Hinke, A. / Windemuth-Kieselbach, C. / Hübner, A. / Burmester, M. / Koenigsmann, M. / Wiegand, J. et al. | 2015
- 1248
-
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind studyRoila, F. / Ruggeri, B. / Ballatori, E. / Fatigoni, S. / Caserta, C. / Licitra, L. / Mirabile, A. / Ionta, M. T. / Massidda, B. / Cavanna, L. et al. | 2015
- 1254
-
Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trialFontein, D. B. / Klinten Grand, M. / Nortier, J. W. / Seynaeve, C. / Meershoek-Klein Kranenbarg, E. / Dirix, L. Y. / van de Velde, C. J. / Putter, H. et al. | 2015
- 1263
-
Life expectancy of colon, breast, and testicular cancer patients: an analysis of US-SEER population-based dataCapocaccia, R. / Gatta, G. / Dal Maso, L. et al. | 2015
- 1269
-
Reply to the letter to the editor ‘Patients' preference and informed consent’ by Pumo et al.Pivot, X. / Machackova, Z. et al. | 2015
- 1269
-
Patients' preference and informed consentPumo, V. / Di Mari, A. / Rametta Giuliano, S. / Bordonaro, S. / Lanteri, E. / Tralongo, P. et al. | 2015
- 1270
-
Concomitant ALK translocation and other non-EGFR gene in NSCLC: knowledge in the makingPassaro, A. / Barberis, M. / Catania, C. / Pessina, S. / de Marinis, F. et al. | 2015
- 1272
-
Reply to the letter to the editor ‘Potential clinical relevant drug–drug interactions: comparison between different compendia, do we have a validated method?’ by Conde-Estévez et al.van Leeuwen, R. W. / Mathijssen, R. H. / Jansman, F. G. / van Gelder, T. et al. | 2015
- 1272
-
Potential clinical relevant drug–drug interactions: comparison between different compendia, do we have a validated method?Conde-Estévez, D. / Echeverría-Esnal, D. / Tusquets, I. / Albanell, J. et al. | 2015
- 1275
-
De-escalation attempts for adjuvant trastuzumab: longer beats shorterCurigliano, G. / Goldhirsch, A. et al. | 2015
- 1277
-
Pharmacokinetic and pharmacodynamic end points with anti-VEGFR: the more it hurts, the more it works?Mir, O. / Dumont, S. / Armand, J. P. et al. | 2015
- 1279
-
‘Industry corner: perspectives and controversies’: a new series in Annals of OncologyDhingra, K. et al. | 2015
- 1280
-
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaborationBossuyt, V. / Provenzano, E. / Symmans, W. F. / Boughey, J. C. / Coles, C. / Curigliano, G. / Dixon, J. M. / Esserman, L. J. / Fastner, G. / Kuehn, T. et al. | 2015
- 1291
-
Genetics of breast cancer: a topic in evolutionShiovitz, S. / Korde, L. A. et al. | 2015
- 1300
-
Alternate sunitinib schedules in patients with metastatic renal cell carcinomaKalra, S. / Rini, B. I. / Jonasch, E. et al. | 2015
- 1305
-
First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysisKasenda, B. / Ferreri, A. J. / Marturano, E. / Forst, D. / Bromberg, J. / Ghesquieres, H. / Ferlay, C. / Blay, J. Y. / Hoang-Xuan, K. / Pulczynski, E. J. et al. | 2015
- 1314
-
The potential for epigenetic analysis of paediatric CNS tumours to improve diagnosis, treatment and prognosisSexton-Oates, A. / MacGregor, D. / Dodgshun, A. / Saffery, R. et al. | 2015
- 1325
-
Consideration of comorbidity in treatment decision making in multidisciplinary cancer team meetings: a systematic reviewStairmand, J. / Signal, L. / Sarfati, D. / Jackson, C. / Batten, L. / Holdaway, M. / Cunningham, C. et al. | 2015
- 1333
-
Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)Mavroudis, D. / Saloustros, E. / Malamos, N. / Kakolyris, S. / Boukovinas, I. / Papakotoulas, P. / Kentepozidis, N. / Ziras, N. / Georgoulias, V. et al. | 2015
- 1340
-
Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trialJamal-Hanjani, M. / A'Hern, R. / Birkbak, N. J. / Gorman, P. / Grönroos, E. / Ngang, S. / Nicola, P. / Rahman, L. / Thanopoulou, E. / Kelly, G. et al. | 2015
- 1346
-
Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancerMoulder, S. / Helgason, T. / Janku, F. / Wheler, J. / Moroney, J. / Booser, D. / Albarracin, C. / Morrow, P. K. / Atkins, J. / Koenig, K. et al. | 2015
- 1353
-
ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patientsTrédan, O. / Ménétrier-Caux, C. / Ray-Coquard, I. / Garin, G. / Cropet, C. / Verronèse, E. / Bachelot, T. / Rebattu, P. / Heudel, P. E. / Cassier, P. et al. | 2015
- 1363
-
Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective studyBeltrame, L. / Di Marino, M. / Fruscio, R. / Calura, E. / Chapman, B. / Clivio, L. / Sina, F. / Mele, C. / Iatropoulos, P. / Grassi, T. et al. | 2015
- 1372
-
Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinomaRini, B. I. / Melichar, B. / Fishman, M. N. / Oya, M. / Pithavala, Y. K. / Chen, Y. / Bair, A. H. / Grünwald, V. et al. | 2015
- 1378
-
RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinomaRavaud, A. / Barrios, C. H. / Alekseev, B. / Tay, M. H. / Agarwala, S. S. / Yalcin, S. / Lin, C. C. / Roman, L. / Shkolnik, M. / Anak, O. et al. | 2015
- 1385
-
Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent linesBodnar, L. / Stec, R. / Cierniak, S. / Synowiec, A. / Wcisło, G. / Jesiotr, M. / Koktysz, R. / Kozłowski, W. / Szczylik, C. et al. | 2015
- 1390
-
High PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy?Mahal, B. A. / Chen, M. H. / Bennett, C. L. / Kattan, M. W. / Sartor, O. / Stein, K. / D'Amico, A. V. / Nguyen, P. L. et al. | 2015
- 1396
-
A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasionLago-Hernandez, C. A. / Feldman, H. / O'Donnell, E. / Mahal, B. A. / Perez, V. / Howard, S. / Rosenthal, M. / Cheng, S. C. / Nguyen, P. L. / Beard, C. et al. | 2015
- 1401
-
A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trialKubota, K. / Sakai, H. / Katakami, N. / Nishio, M. / Inoue, A. / Okamoto, H. / Isobe, H. / Kunitoh, H. / Takiguchi, Y. / Kobayashi, K. et al. | 2015
- 1408
-
High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancerPailler, E. / Auger, N. / Lindsay, C. R. / Vielh, P. / Islas-Morris-Hernandez, A. / Borget, I. / Ngo-Camus, M. / Planchard, D. / Soria, J. C. / Besse, B. et al. | 2015
- 1415
-
Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancerâ€Lim, C. / Tsao, M. S. / Le, L. W. / Shepherd, F. A. / Feld, R. / Burkes, R. L. / Liu, G. / Kamel-Reid, S. / Hwang, D. / Tanguay, J. et al. | 2015
- 1421
-
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumorsKris, M. G. / Camidge, D. R. / Giaccone, G. / Hida, T. / Li, B. T. / O'Connell, J. / Taylor, I. / Zhang, H. / Arcila, M. E. / Goldberg, Z. et al. | 2015
- 1427
-
FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE studyâ€Iwamoto, S. / Takahashi, T. / Tamagawa, H. / Nakamura, M. / Munemoto, Y. / Kato, T. / Hata, T. / Denda, T. / Morita, Y. / Inukai, M. et al. | 2015
- 1434
-
Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML—long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL)â€Thiel, A. / Schetelig, J. / Pönisch, W. / Schäfer-Eckart, K. / Aulitzky, W. / Peter, N. / Schulze, A. / Maschmeyer, G. / Neugebauer, S. / Herbst, R. et al. | 2015
- 1440
-
Differences in attitudes and beliefs toward end-of-life care between hematologic and solid tumor oncology specialistsHui, D. / Bansal, S. / Park, M. / Reddy, A. / Cortes, J. / Fossella, F. / Bruera, E. et al. | 2015
- 1446
-
Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort studyâ€Cheung, Y. T. / Ng, T. / Shwe, M. / Ho, H. K. / Foo, K. M. / Cham, M. T. / Lee, J. A. / Fan, G. / Tan, Y. P. / Yong, W. S. et al. | 2015
- 1452
-
The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapyLyman, G. H. / Reiner, M. / Morrow, P. K. / Crawford, J. et al. | 2015
- 1459
-
Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM modelChugh, R. / Griffith, K. A. / Davis, E. J. / Thomas, D. G. / Zavala, J. D. / Metko, G. / Brockstein, B. / Undevia, S. D. / Stadler, W. M. / Schuetze, S. M. et al. | 2015
- 1465
-
Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II studyToulmonde, M. / Le Cesne, A. / Piperno-Neumann, S. / Penel, N. / Chevreau, C. / Duffaud, F. / Bellera, C. / Italiano, A. et al. | 2015
- 1470
-
Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and toleranceâ€Funck-Brentano, E. / Alvarez, J. C. / Longvert, C. / Abe, E. / Beauchet, A. / Funck-Brentano, C. / Saiag, P. et al. | 2015
- 1476
-
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinomaMassarelli, E. / Lin, H. / Ginsberg, L. E. / Tran, H. T. / Lee, J. J. / Canales, J. R. / Williams, M. D. / Blumenschein, G. R. / Lu, C. / Heymach, J. V. et al. | 2015
- 1481
-
Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumorsâ€Rosenthal, E. L. / Chung, T. K. / Parker, W. B. / Allan, P. W. / Clemons, L. / Lowman, D. / Hong, J. / Hunt, F. R. / Richman, J. / Conry, R. M. et al. | 2015
- 1488
-
PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytesAli, H. R. / Glont, S. E. / Blows, F. M. / Provenzano, E. / Dawson, S. J. / Liu, B. / Hiller, L. / Dunn, J. / Poole, C. J. / Bowden, S. et al. | 2015
- 1494
-
Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) statusNuciforo, P. G. / Aura, C. / Holmes, E. / Prudkin, L. / Jimenez, J. / Martinez, P. / Ameels, H. / de la Peña, L. / Ellis, C. / Eidtmann, H. et al. | 2015
- 1500
-
Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon modelJovelet, C. / Seck, A. / Mir, O. / Simasotchi, C. / Broutin, S. / Goffinet, F. / Bidart, J. M. / Paci, A. / Gil, S. et al. | 2015
- 1504
-
Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitorsStewart, A. / Thavasu, P. / de Bono, J. S. / Banerji, U. et al. | 2015
- 1511
-
Duration of endocrine therapy and its impact on the results of adjuvant trials in premenopausal breast cancer patientsFouad, T. M. / de Azambuja, E. / Azim, H. A. et al. | 2015
- 1511
-
Sunitinib 2 weeks on, 1 off: strengths and weaknessesIacovelli, R. / Verri, E. / Cossu Rocca, M. / Aurilio, G. / Cullurà , D. / Nolé, F. et al. | 2015
- 1512
-
Alternative sunitinib schedules in metastatic renal cell carcinoma and the RAINBOW studyBracarda, S. et al. | 2015
- 1513
-
Agenda science: turning nothing into something: a response to the editorial by Oldenburg et al. and its featured article by Vidal et al.Kollmannsberger, C. / Nichols, C. et al. | 2015
- 1514
-
ALK FISH rearranged and amplified tumor with negative immunohistochemistry: a rare and challenging case concerning ALK status screening in lung cancerUguen, A. / Talagas, M. / Andrieu-Key, S. / Costa, S. / Quintin-Roué, I. / De Braekeleer, M. / Marcorelles, P. et al. | 2015
- 1515
-
Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinibSpraggs, C. F. / Parham, L. R. / Song, K. / Briley, L. P. / Johnson, T. / Russo, M. / Tada, H. / du Bois, A. / Xu, C. F. et al. | 2015
- 1518
-
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter studyDieci, M. V. / Criscitiello, C. / Goubar, A. / Viale, G. / Conte, P. / Guarneri, V. / Ficarra, G. / Mathieu, M. C. / Delaloge, S. / Curigliano, G. et al. | 2015
- 1805
-
Androgen receptor splice variant V7 (AR-V7) in circulating tumor cells: a coming of age for AR splice variants?Sprenger, C. / Uo, T. / Plymate, S. et al. | 2015
- 1808
-
Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trialsPaoletti, X. / Ezzalfani, M. / Le Tourneau, C. et al. | 2015
- 1813
-
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?Apetoh, L. / Ladoire, S. / Coukos, G. / Ghiringhelli, F. et al. | 2015
- 1824
-
A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors†Chen, T. W. / Razak, A. R. / Bedard, P. L. / Siu, L. L. / Hansen, A. R. et al. | 2015
- 1830
-
A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicineHeuckmann, J. M. / Thomas, R. K. et al. | 2015
- 1838
-
Implementation of supportive care and best supportive care interventions in clinical trials enrolling patients with cancer†Lee, R. T. / Ramchandran, K. / Sanft, T. / Von Roenn, J. et al. | 2015
- 1846
-
Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factorsHowell, D. / Molloy, S. / Wilkinson, K. / Green, E. / Orchard, K. / Wang, K. / Liberty, J. et al. | 2015
- 1859
-
Serial blood-based analysis of AR-V7 in men with advanced prostate cancerNakazawa, M. / Lu, C. / Chen, Y. / Paller, C. J. / Carducci, M. A. / Eisenberger, M. A. / Luo, J. / Antonarakis, E. S. et al. | 2015
- 1865
-
Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ-cell tumour: results from a 17-year UK experienceChau, C. / Cathomas, R. / Wheater, M. / Klingbiel, D. / Fehr, M. / Bennett, J. / Markham, H. / Lee, C. / Crabb, S. J. / Geldart, T. et al. | 2015
- 1871
-
Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinomaNaito, S. / Sakai, H. / Hashine, K. / Tomita, Y. / Shinohara, N. / Fujisawa, M. / Eto, M. / Ozono, S. / Akaza, H. et al. | 2015
- 1877
-
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)Zhou, C. / Wu, Y. L. / Chen, G. / Feng, J. / Liu, X. Q. / Wang, C. / Zhang, S. / Wang, J. / Zhou, S. / Ren, S. et al. | 2015
- 1883
-
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study†Wu, Y. L. / Zhou, C. / Liam, C. K. / Wu, G. / Liu, X. / Zhong, Z. / Lu, S. / Cheng, Y. / Han, B. / Chen, L. et al. | 2015
- 1890
-
Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)—first results from PathIES†Speirs, V. / Viale, G. / Mousa, K. / Palmieri, C. / Reed, S. N. / Nicholas, H. / Cheang, M. / Jassem, J. / Lønning, P. E. / Kalaitzaki, E. et al. | 2015
- 1898
-
Population-based analysis of the impact and generalizability of the NSABP-B24 study on endocrine therapy for patients with ductal carcinoma in situ of the breast†Lo, A. C. / Truong, P. T. / Wai, E. S. / Nichol, A. / Weir, L. / Speers, C. / Hayes, M. M. / Baliski, C. / Tyldesley, S. et al. | 2015
- 1904
-
Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancerDiéras, V. / Campone, M. / Yardley, D. A. / Romieu, G. / Valero, V. / Isakoff, S. J. / Koeppen, H. / Wilson, T. R. / Xiao, Y. / Shames, D. S. et al. | 2015
- 1910
-
Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studiesGrenader, T. / Nash, S. / Plotkin, Y. / Furuse, J. / Mizuno, N. / Okusaka, T. / Wasan, H. / Valle, J. / Bridgewater, J. et al. | 2015
- 1916
-
Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05)Tanabe, K. / Fujii, M. / Nishikawa, K. / Kunisaki, C. / Tsuji, A. / Matsuhashi, N. / Takagane, A. / Ohno, T. / Kawase, T. / Kochi, M. et al. | 2015
- 1923
-
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer†O'Neil, B. H. / Scott, A. J. / Ma, W. W. / Cohen, S. J. / Aisner, D. L. / Menter, A. R. / Tejani, M. A. / Cho, J. K. / Granfortuna, J. / Coveler, L. et al. | 2015
- 1930
-
Survival after resection of perihilar cholangiocarcinoma—development and external validation of a prognostic nomogramGroot Koerkamp, B. / Wiggers, J. K. / Gonen, M. / Doussot, A. / Allen, P. J. / Besselink, M. G. / Blumgart, L. H. / Busch, O. R. / D'Angelica, M. I. / DeMatteo, R. P. et al. | 2015
- 1936
-
Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trialSclafani, F. / Chau, I. / Cunningham, D. / Peckitt, C. / Lampis, A. / Hahne, J. C. / Braconi, C. / Tabernero, J. / Glimelius, B. / Cervantes, A. et al. | 2015
- 1941
-
Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC studyGuigay, J. / Fayette, J. / Dillies, A. F. / Sire, C. / Kerger, J. N. / Tennevet, I. / Machiels, J. P. / Zanetta, S. / Pointreau, Y. / Bozec Le Moal, L. et al. | 2015
- 1948
-
Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapyBlackwell, K. / Semiglazov, V. / Krasnozhon, D. / Davidenko, I. / Nelyubina, L. / Nakov, R. / Stiegler, G. / Singh, P. / Schwebig, A. / Kramer, S. et al. | 2015
- 1953
-
Indicators of integration of oncology and palliative care programs: an international consensusHui, D. / Bansal, S. / Strasser, F. / Morita, T. / Caraceni, A. / Davis, M. / Cherny, N. / Kaasa, S. / Currow, D. / Abernethy, A. et al. | 2015
- 1960
-
High anabolic potential of essential amino acid mixtures in advanced nonsmall cell lung cancerEngelen, M. P. / Safar, A. M. / Bartter, T. / Koeman, F. / Deutz, N. E. et al. | 2015
- 1966
-
Planning and reporting of quality-of-life outcomes in cancer trialsSchandelmaier, S. / Conen, K. / von Elm, E. / You, J. J. / Blümle, A. / Tomonaga, Y. / Amstutz, A. / Briel, M. / Kasenda, B. et al. | 2015
- 1974
-
Association between information provision and decisional conflict in cancer patientsSim, J. A. / Shin, J. S. / Park, S. M. / Chang, Y. J. / Shin, A. / Noh, D. Y. / Han, W. / Yang, H. K. / Lee, H. J. / Kim, Y. W. et al. | 2015
- 1980
-
The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600Massi, D. / Brusa, D. / Merelli, B. / Falcone, C. / Xue, G. / Carobbio, A. / Nassini, R. / Baroni, G. / Tamborini, E. / Cattaneo, L. et al. | 2015
- 1987
-
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)†Grande, E. / Capdevila, J. / Castellano, D. / Teulé, A. / Durán, I. / Fuster, J. / Sevilla, I. / Escudero, P. / Sastre, J. / García-Donas, J. et al. | 2015
- 1994
-
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancerBarault, L. / Amatu, A. / Bleeker, F. E. / Moutinho, C. / Falcomatà, C. / Fiano, V. / Cassingena, A. / Siravegna, G. / Milione, M. / Cassoni, P. et al. | 2015
- 2000
-
Cross-over—it's a feature, not a bugEngelsberg, A. et al. | 2015
- 2003
-
Flaws in the trial design of IFCT-0802Gyawali, B. / Shimokata, T. / Honda, K. / Ando, Y. et al. | 2015
- 2003
-
Does activity of anticancer drugs in advanced cancer always translates in effectivity in early-stage high-risk disease?Schrijvers, D. L. et al. | 2015
- 2007
-
Tivantinib added to erlotinib in nonsmall-cell lung cancer: the primary end point was not MET…Scagliotti, G. V. / Di Maio, M. et al. | 2015
- 2010
-
Academically led clinical trials: challenges and opportunitiesTurajlic, S. / Larkin, J. / Swanton, C. et al. | 2015
- 2012
-
Statistical controversies in clinical research: an initial evaluation of a surrogate end point using a single randomized clinical trial and the Prentice criteriaHeller, G. et al. | 2015
- 2017
-
Regorafenib-associated hand–foot skin reaction: practical advice on diagnosis, prevention, and managementMcLellan, B. / Ciardiello, F. / Lacouture, M. E. / Segaert, S. / Van Cutsem, E. et al. | 2015
- 2026
-
The new therapeutical scenario of Hodgkin lymphomaStathis, A. / Younes, A. et al. | 2015
- 2034
-
Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatmentsLedermann, J. A. / Canevari, S. / Thigpen, T. et al. | 2015
- 2044
-
Treatment of mCRPC in the AR-axis-targeted therapy-resistant stateChi, K. / Hotte, S. J. / Joshua, A. M. / North, S. / Wyatt, A. W. / Collins, L. L. / Saad, F. et al. | 2015
- 2057
-
BRCA1 and BRCA2 genetic testing—pitfalls and recommendations for managing variants of uncertain clinical significanceEccles, D. M. / Mitchell, G. / Monteiro, A. N. / Schmutzler, R. / Couch, F. J. / Spurdle, A. B. / Gómez-García, E. B. et al. | 2015
- 2066
-
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)Yoshioka, H. / Azuma, K. / Yamamoto, N. / Takahashi, T. / Nishio, M. / Katakami, N. / Ahn, M. J. / Hirashima, T. / Maemondo, M. / Kim, S. W. et al. | 2015
- 2073
-
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patientsPlanchard, D. / Loriot, Y. / André, F. / Gobert, A. / Auger, N. / Lacroix, L. / Soria, J. C. et al. | 2015
- 2079
-
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trialRulli, E. / Marabese, M. / Torri, V. / Farina, G. / Veronese, S. / Bettini, A. / Longo, F. / Moscetti, L. / Ganzinelli, M. / Lauricella, C. et al. | 2015
- 2085
-
A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patientsVan Cutsem, E. / Prenen, H. / D'Haens, G. / Bennouna, J. / Carrato, A. / Ducreux, M. / Bouché, O. / Sobrero, A. / Latini, L. / Staines, H. et al. | 2015
- 2092
-
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosisCremolini, C. / Di Bartolomeo, M. / Amatu, A. / Antoniotti, C. / Moretto, R. / Berenato, R. / Perrone, F. / Tamborini, E. / Aprile, G. / Lonardi, S. et al. | 2015
- 2097
-
Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)Ryu, M. H. / Baba, E. / Lee, K. H. / Park, Y. I. / Boku, N. / Hyodo, I. / Nam, B. H. / Esaki, T. / Yoo, C. / Ryoo, B. Y. et al. | 2015
- 2102
-
Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancerJiang, D. M. / Raissouni, S. / Mercer, J. / Kumar, A. / Goodwin, R. / Heng, D. Y. / Tang, P. A. / Doll, C. / MacLean, A. / Powell, E. et al. | 2015
- 2107
-
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysisBracarda, S. / Iacovelli, R. / Boni, L. / Rizzo, M. / Derosa, L. / Rossi, M. / Galli, L. / Procopio, G. / Sisani, M. / Longo, F. et al. | 2015
- 2113
-
Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial designGerety, E. L. / Lawrence, E. M. / Wason, J. / Yan, H. / Hilborne, S. / Buscombe, J. / Cheow, H. K. / Shaw, A. S. / Bird, N. / Fife, K. et al. | 2015
- 2119
-
Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) studyLibé, R. / Borget, I. / Ronchi, C. L. / Zaggia, B. / Kroiss, M. / Kerkhofs, T. / Bertherat, J. / Volante, M. / Quinkler, M. / Chabre, O. et al. | 2015
- 2125
-
Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumorsNieto, Y. / Tu, S. M. / Bassett, R. / Jones, R. B. / Gulbis, A. M. / Tannir, N. / Kingham, A. / Ledesma, C. / Margolin, K. / Holmberg, L. et al. | 2015
- 2133
-
Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factorsSprauten, M. / Haugnes, H. S. / Brydøy, M. / Kiserud, C. / Tandstad, T. / Bjøro, T. / Bjerner, J. / Cvancarova, M. / Fosså, S. D. / Oldenburg, J. et al. | 2015
- 2141
-
A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancerDijkgraaf, E. M. / Santegoets, S. J. / Reyners, A. K. / Goedemans, R. / Wouters, M. C. / Kenter, G. G. / van Erkel, A. R. / van Poelgeest, M. I. / Nijman, H. W. / van der Hoeven, J. J. et al. | 2015
- 2149
-
Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trialUeda, T. / Morioka, H. / Nishida, Y. / Kakunaga, S. / Tsuchiya, H. / Matsumoto, Y. / Asami, Y. / Inoue, T. / Yoneda, T. et al. | 2015
- 2155
-
FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS riskSpina, M. / Nagy, Z. / Ribera, J. M. / Federico, M. / Aurer, I. / Jordan, K. / Borsaru, G. / Pristupa, A. S. / Bosi, A. / Grosicki, S. et al. | 2015
- 2161
-
Has racial difference in cause-specific death improved in older patients with late-stage breast cancer?Ning, J. / Peng, S. / Ueno, N. / Xu, Y. / Shih, Y. / Karuturi, M. / Giordano, S. / Shen, Y. et al. | 2015
- 2168
-
Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)†Bompas, E. / Le Cesne, A. / Tresch-Bruneel, E. / Lebellec, L. / Laurence, V. / Collard, O. / Saada-Bouzid, E. / Isambert, N. / Blay, J. Y. / Amela, E. Y. et al. | 2015
- 2173
-
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanomaMiddleton, M. R. / Friedlander, P. / Hamid, O. / Daud, A. / Plummer, R. / Falotico, N. / Chyla, B. / Jiang, F. / McKeegan, E. / Mostafa, N. M. et al. | 2015
- 2180
-
Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer modelMaia, A. R. / de Man, J. / Boon, U. / Janssen, A. / Song, J. Y. / Omerzu, M. / Sterrenburg, J. G. / Prinsen, M. B. / Willemsen-Seegers, N. / de Roos, J. A. et al. | 2015
- 2193
-
Health care in the United States—basic human right or entitlement?Jones, G. H. / Kantarjian, H. et al. | 2015
- 2196
-
Reply to the letter to the editor ‘Ablative therapies for lung metastases: a need to acknowledge the efficacy and toxicity of stereotactic ablative body radiotherapy’ by Siva et al.de Baère, T. / Aupérin, A. / Deschamps, F. / Chevallier, P. / Gaubert, Y. / Boige, V. / Fonck, M. / Escudier, B. / Palussiére, J. et al. | 2015
- 2196
-
Ablative therapies for lung metastases: a need to acknowledge the efficacy and toxicity of stereotactic ablative body radiotherapySiva, S. / Senan, S. / Ball, D. et al. | 2015
- 2197
-
Primum non nocereTempleton, A. J. / Šeruga, B. et al. | 2015
- 2198
-
Reply to letter to the editor ‘Primum non nocere’ by Templeton and ŠerugaAapro, M. / Moebus, V. / Nitz, U. / O'Shaughnessy, J. / Pronzato, P. / Untch, M. / Tomita, D. / Bohac, C. / Leyland-Jones, B. et al. | 2015
- 2199
-
MiR-29c downregulation contributes to metastatic progression in colorectal cancerCristóbal, I. / Madoz-Gúrpide, J. / Manso, R. / Rojo, F. / García-Foncillas, J. et al. | 2015
- 2199
-
Reply to the letter to the editor ‘Flaws in the trial design of IFCT-0802’ by Gyawali et al.Pujol, J. L. / Morin, F. / Zalcman, G. et al. | 2015
- 2200
-
Reply to the letter to the editor ‘Journey to a faraway land’ by Alkan et al.Hartkopf, A. D. / Brucker, S. Y. / Taran, F. A. et al. | 2015
- 2200
-
Journey to a faraway landAlkan, A. / Karcı, E. / Utkan, G. et al. | 2015
- 2203
-
Is chemotherapy still an option in the treatment of melanoma?Carlino, M. S. / Long, G. V. et al. | 2015
- 2205
-
Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysisIbrahim, M. F. / Mazzarello, S. / Shorr, R. / Vandermeer, L. / Jacobs, C. / Hilton, J. / Hutton, B. / Clemons, M. et al. | 2015
- 2213
-
Why has active immunotherapy not worked in lung cancer?Thomas, A. / Giaccone, G. et al. | 2015
- 2221
-
Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer—going beyond PSA and imaging, a systematic literature reviewSchmid, S. / Omlin, A. / Blum, D. / Strasser, F. / Gillessen, S. / Rothermundt, C. et al. | 2015
- 2247
-
Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factorsDimopoulos, M. A. / Sonneveld, P. / Siegel, D. / Palumbo, A. / San-Miguel, J. et al. | 2015
- 2257
-
Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studiesGenkinger, J. M. / Kitahara, C. M. / Bernstein, L. / Berrington de Gonzalez, A. / Brotzman, M. / Elena, J. W. / Giles, G. G. / Hartge, P. / Singh, P. N. / Stolzenberg-Solomon, R. Z. et al. | 2015
- 2267
-
A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanomaHersh, E. M. / Del Vecchio, M. / Brown, M. P. / Kefford, R. / Loquai, C. / Testori, A. / Bhatia, S. / Gutzmer, R. / Conry, R. / Haydon, A. et al. | 2015
- 2274
-
Randomized phase III trial of treatment duration for oral uracil and tegafur plus leucovorin as adjuvant chemotherapy for patients with stage IIB/III colon cancer: final results of JFMC33-0502Sadahiro, S. / Tsuchiya, T. / Sasaki, K. / Kondo, K. / Katsumata, K. / Nishimura, G. / Kakeji, Y. / Baba, H. / Sato, S. / Koda, K. et al. | 2015
- 2280
-
A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trialDavidson, A. / Veillard, A. S. / Tognela, A. / Chan, M. M. / Hughes, B. G. / Boyer, M. / Briscoe, K. / Begbie, S. / Abdi, E. / Crombie, C. et al. | 2015
- 2286
-
A randomized phase II study comparing paclitaxel–carboplatin–bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†Dingemans, A. M. / Groen, H. J. / Herder, G. J. / Stigt, J. A. / Smit, E. F. / Bahce, I. / Burgers, J. A. / van den Borne, B. E. / Biesma, B. / Vincent, A. et al. | 2015
- 2293
-
High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriersCastro, E. / Jugurnauth-Little, S. / Karlsson, Q. / Al-Shahrour, F. / Piñeiro-Yañez, E. / Van de Poll, F. / Leongamornlert, D. / Dadaev, T. / Govindasami, K. / Guy, M. et al. | 2015
- 2300
-
RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trialLee, J. L. / Kim, M. K. / Park, I. / Ahn, J. H. / Lee, D. H. / Ryoo, H. M. / Song, C. / Hong, B. / Hong, J. H. / Ahn, H. et al. | 2015
- 2305
-
Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivorsBoer, H. / Proost, J. H. / Nuver, J. / Bunskoek, S. / Gietema, J. Q. / Geubels, B. M. / Altena, R. / Zwart, N. / Oosting, S. F. / Vonk, J. M. et al. | 2015
- 2311
-
Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†Casulo, C. / Day, B. / Dawson, K. L. / Zhou, X. / Flowers, C. R. / Farber, C. M. / Hainsworth, J. D. / Cerhan, J. R. / Link, B. K. / Zelenetz, A. D. et al. | 2015
- 2317
-
Life expectancy of young adults with follicular lymphomaConconi, A. / Lobetti-Bodoni, C. / Montoto, S. / Lopez-Guillermo, A. / Coutinho, R. / Matthews, J. / Franceschetti, S. / Bertoni, F. / Moccia, A. / Rancoita, P. M. et al. | 2015
- 2323
-
Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphomaGraf, S. A. / Stevenson, P. A. / Holmberg, L. A. / Till, B. G. / Press, O. W. / Chauncey, T. R. / Smith, S. D. / Philip, M. / Orozco, J. J. / Shustov, A. R. et al. | 2015
- 2329
-
Histologic transformation in marginal zone lymphomas†Conconi, A. / Franceschetti, S. / Aprile von Hohenstaufen, K. / Margiotta-Casaluci, G. / Stathis, A. / Moccia, A. A. / Bertoni, F. / Ramponi, A. / Mazzucchelli, L. / Cavalli, F. et al. | 2015
- 2335
-
Development and validation of a nomogram to predict survival in incurable cachectic cancer patients on home parenteral nutritionBozzetti, F. / Cotogni, P. / Lo Vullo, S. / Pironi, L. / Giardiello, D. / Mariani, L. et al. | 2015
- 2341
-
A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumorsde Braud, F. / Cascinu, S. / Spitaleri, G. / Pilz, K. / Clementi, L. / Liu, D. / Sikken, P. / De Pas, T. et al. | 2015
- 2347
-
Oncology 2020: a drug development and approval paradigmDhingra, K. et al. | 2015
- 2351
-
Evaluation of tumor-infiltrating lymphocytes in breast cancer; proposal of a simpler methodHida, A. I. / Ohi, Y. et al. | 2015
- 2352
-
New life for retrospective study in the precision oncology eraOrlandi, A. / Basso, M. / Calegari, M. A. / Barone, C. et al. | 2015
- 2352
-
Adjuvant chemotherapy after preoperative chemoradiotherapy for rectal cancerKanyilmaz, G. / Koc, M. / Aktan, M. et al. | 2015
- 2353
-
Reply to the letter to the editor ‘New life for retrospective study in the Precision Oncology Era’ by Orlandi et al.Pietrantonio, F. / Cremolini, C. et al. | 2015
- 2354
-
Management of advanced prostate cancervon Eyben, F. / Kiljunen, T. / Kangasmaki, A. / Kairemo, K. / von Eyben, R. / Joensuu, T. et al. | 2015
- 2354
-
Reply to the letter to the editor ‘Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015’ by Gillessen et al.Gillessen, S. / Fanti, S. / Omlin, A. et al. | 2015
- 2355
-
Hemorrhagic cystitis in a patient without a past history of radiation therapy who was treated with cabazitaxel for CRPCKosaka, T. / Oya, M. et al. | 2015
- 2356
-
Era-by-era improvement in survival for elderly patients with Hodgkin lymphoma; outcome data from a large population-based cohortBishton, M. J. / Hubbard, R. / Witherall, R. / Jones, S. G. / Richardson, F. / James, E. J. / Sovani, V. / Bessell, E. M. / Haynes, A. P. / McMillan, A. K. et al. | 2015
- 2357
-
The ESMO magnitude of clinical benefit scaling tool: from theory to practiceHartmann, M. et al. | 2015
- 2359
-
REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumoursLévy, C. / Allouache, D. / Lacroix, J. / Dugué, A. E. / Supiot, S. / Campone, M. / Mahe, M. / Kichou, S. / Leheurteur, M. / Hanzen, C. et al. | 2015
- 2361
-
Immunity and HER2-positive disease: never stop questioningLoi, S. et al. | 2015
- 2363
-
Statistical controversies in clinical research: long-term follow-up of clinical trials in cancerCuzick, J. et al. | 2015
- 2367
-
Targeting the undruggable: immunotherapy meets personalized oncology in the genomic eraMartin, S. D. / Coukos, G. / Holt, R. A. / Nelson, B. H. et al. | 2015
- 2375
-
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodiesNaidoo, J. / Page, D. B. / Li, B. T. / Connell, L. C. / Schindler, K. / Lacouture, M. E. / Postow, M. A. / Wolchok, J. D. et al. | 2015
- 2392
-
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†Kramar, A. / Negrier, S. / Sylvester, R. / Joniau, S. / Mulders, P. / Powles, T. / Bex, A. / Bonnetain, F. / Bossi, A. / Bracarda, S. et al. | 2015
- 2398
-
Breastfeeding and breast cancer risk by receptor status—a systematic review and meta-analysisIslami, F. / Liu, Y. / Jemal, A. / Zhou, J. / Weiderpass, E. / Colditz, G. / Boffetta, P. / Weiss, M. et al. | 2015
- 2408
-
Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studiesLambertini, M. / Ceppi, M. / Poggio, F. / Peccatori, F. A. / Azim, H. A. / Ugolini, D. / Pronzato, P. / Loibl, S. / Moore, H. C. / Partridge, A. H. et al. | 2015
- 2419
-
Designs of preoperative biomarkers trials in oncology: a systematic review of the literatureMarous, M. / Bièche, I. / Paoletti, X. / Alt, M. / Razak, A. R. / Stathis, A. / Kamal, M. / Le Tourneau, C. et al. | 2015
- 2429
-
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trialBianchini, G. / Pusztai, L. / Pienkowski, T. / Im, Y. H. / Bianchi, G. V. / Tseng, L. M. / Liu, M. C. / Lluch, A. / Galeota, E. / Magazzù, D. et al. | 2015
- 2437
-
A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor (‘SPROG’ trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRNLeonard, R. C. / Mansi, J. L. / Keerie, C. / Yellowlees, A. / Crawford, S. / Benstead, K. / Matthew, R. / Adamson, D. / Chan, S. / Grieve, R. et al. | 2015
- 2442
-
Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trialMunzone, E. / Giobbie-Hurder, A. / Gusterson, B. A. / Mallon, E. / Viale, G. / Thürlimann, B. / Ejlertsen, B. / MacGrogan, G. / Bibeau, F. / Lelkaitis, G. et al. | 2015
- 2450
-
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trialsSunakawa, Y. / Stintzing, S. / Cao, S. / Heinemann, V. / Cremolini, C. / Falcone, A. / Yang, D. / Zhang, W. / Ning, Y. / Stremitzer, S. et al. | 2015
- 2457
-
Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinomaKang, Y. K. / Yau, T. / Park, J. W. / Lim, H. Y. / Lee, T. Y. / Obi, S. / Chan, S. L. / Qin, S. / Kim, R. D. / Casey, M. et al. | 2015
- 2464
-
The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancerMiddleton, G. / Crack, L. R. / Popat, S. / Swanton, C. / Hollingsworth, S. J. / Buller, R. / Walker, I. / Carr, T. H. / Wherton, D. / Billingham, L. J. et al. | 2015
- 2470
-
Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancerMichels, J. / Adam, J. / Goubar, A. / Obrist, F. / Damotte, D. / Robin, A. / Alifano, M. / Vitale, I. / Olaussen, K. A. / Girard, P. et al. | 2015
- 2477
-
Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancerTakeda, M. / Sakai, K. / Terashima, M. / Kaneda, H. / Hayashi, H. / Tanaka, K. / Okamoto, K. / Takahama, T. / Yoshida, T. / Iwasa, T. et al. | 2015
- 2483
-
A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesotheliomaNowak, A. K. / Cook, A. M. / McDonnell, A. M. / Millward, M. J. / Creaney, J. / Francis, R. J. / Hasani, A. / Segal, A. / Musk, A. W. / Turlach, B. A. et al. | 2015
- 2490
-
Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institutionHosing, C. / Bassett, R. / Dabaja, B. / Talpur, R. / Alousi, A. / Ciurea, S. / Popat, U. / Qazilbash, M. / Shpall, E. J. / Oki, Y. et al. | 2015
- 2496
-
Alopecia in patients treated with molecularly targeted anticancer therapiesBelum, V. R. / Marulanda, K. / Ensslin, C. / Gorcey, L. / Parikh, T. / Wu, S. / Busam, K. J. / Gerber, P. A. / Lacouture, M. E. et al. | 2015
- 2503
-
Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancerSchirripa, M. / Loupakis, F. / Lonardi, S. / Cremolini, C. / Bergamo, F. / Zagonel, V. / Falcone, A. et al. | 2015
- 2504
-
Comment on ESMO Magnitude of Clinical Benefit ScaleMuhonen, T. / Joensuu, H. / Pfeiffer, P. et al. | 2015
- i1
-
1PD AN INTEGRATIVE ANALYSIS OF THE PUTATIVE GEFITINIB-RESISTANT GENES IN A LUNG CANCER CELL LINE MODEL SYSTEMHan, X. / Liu, M. / Wang, S. / Qian, X. / Lv, G. / Ma, L. / Zeng, C. / Shi, Y. et al. | 2015
- i1
-
2P EGFR MUTATION IS NOT A RARE ISSUE FOR PERIPHERAL SQUAMOUS CARCINOMA OF LUNGZhang, Q. / Zhu, L. / Gu, P. / Zhang, Y. / Han, B. / Zhang, J. et al. | 2015
- i1
-
3P EGFR MUTATIONS IN NON-SMALL CELL LUNG CANCER IN SOUTH AFRICAChan, S. W. / Maske, C. P. / Ruff, P. et al. | 2015
- i1
-
5P RELIABLE EGFR MUTATION TESTING IN ULTRASOUND GUIDED SUPRACLAVICULAR LYMPH NODE FINE NEEDLE ASPIRATES: A COHORT STUDY WITH DIAGNOSTIC PERFORMANCE ANALYSISAwwad, A. / Tiwari, S. / Sovani, V. / Baldwin, D. / Kumaran, M. et al. | 2015
- i2
-
8P PD1/PD-L1 EXPRESSION IN NSCLC DIFFERS ACCORDING TO LOCALISATION, GRADING AND SUBTYPEBr�hl, F. / Csanadi, A. / Kayser, C. / Wiesemann, S. / Rawluk, J. / Werner, M. / Kayser, G. et al. | 2015
- i2
-
6P SCREENING FOR THE PREVALENCE OF EGFR AND ALK MUTATIONS IN LUNG ADENOCARCINOMA PATIENTS IN THE LEVANT AREA, A PROSPECTIVE ANALYSISTfayli, A. / Khalil, M. / Mina, A. / Rafei, H. / Fakhreddin, N. / Mahfouz, R. / Farhat, F. / Hamouri, S. / Dbouk, H. / Zaatari, G. et al. | 2015
- i2
-
7P FREQUENCY OF ALK GENE REARRANGEMENT IN SAUDI LUNG CANCERAl Dayel, F. H. / Al Husaini, H. / Mohammed, S. / Tulbah, A. / Al Kuraya, K. et al. | 2015
- i3
-
10P ALLELE FREQUENCY OF ABO AND RH BLOOD GROUP AND THE RISK OF NON SMALL CELL LUNG CARCINOMAKapoor, A. / Kumar, N. / Kalwar, A. / Narayan, S. / Nirban, R. K. / Jakhar, S. L. / Beniwal, S. K. / Sharma, N. / Kumar, H. S. / Sharma, A. et al. | 2015
- i3
-
11P THE COMPARATIVE ESTIMATION OF ESTROGEN RECEPTOR BETA EXPRESSION IN PRIMARY AND METASTATIC LUNG CANCERBogush, T. A. / Dudko, E. A. / Bogush, E. A. / Kirsanov, V. J. / Grishanina, A. N. / Ramanauskaite, R. J. / Polotsky, B. E. / Tjulandin, S. / Davydov, M. I. et al. | 2015
- i3
-
9P DISTRIBUTION OF T CELLS IN NON-SMALL CELL LUNG CANCER TISSUE ACCORDING TO COPD AND SMOKING STATUSJackute, J. / Zemaitis, M. / Pranys, D. / Sitkauskiene, B. / Miliauskas, S. / Sakalauskas, R. et al. | 2015
- i3
-
12P A MOLECULAR CASECONTROL INVESTIGATION OF THE MERKEL CELL POLYOMAVIRUS PREVALENCE IN VIETNAMESE NON-SMALL-CELL LUNG-CANCERNgo, T. T. et al. | 2015
- i4
-
15P CLINICOPATHOLOGICAL ANALYSIS OF PRIMARY PULMONARY LYMPHOEPITHELIOMA-LIKE CARCINOMAShen, C. / Che, G. et al. | 2015
- i4
-
13P EXPRESSION OF IRAK-1 AND EZH-2 IN IMPRINTS OF NSCLC AND PRENEOPLASTIC LESIONSHainis, K. / Athanassiadou, A. M. / Haini, E. / Tsipis, A. / Gonidi, M. / Athanassiadou, P. et al. | 2015
- i4
-
16P COMPREHENSIVE ANALYSIS OF DRIVER MUTATIONS IN CHINESE SQUAMOUS CELL LUNG CARCINOMAS BY TARGETED NEXT-GENERATION SEQUENCINGShi, Y. / Tao, D. / Yang, S. / Han, X. / Wu, D. / Zhang, N. et al. | 2015
- i4
-
14P DIFFERENT TREND IN MULTIPLE PRIMARY LUNG CANCER AND INTRAPULMONARY METASTASISShen, C. / Che, G. et al. | 2015
- i5
-
19P FINE NEEDLE ASPIRATION CYTOLOGY OF THYMIC EPITHELIAL NEOPLASMS: A CYTOLOGIC-HISTOLOGIC CORRELATION ANALYSIS FROM A REFERRAL INSTITUTIONTemplo, F. J. et al. | 2015
- i5
-
17P IDENTIFYING THE GENETIC LANDSCAPE OF SQUAMOUS CELL CARCINOMA (SCC) AND ADENOSQUAMOUS CARCINOMA (ASC) OF THE LUNG USING NEXT-GENERATION SEQUENCING (NGS)Chilingirova, N. / Balabanski, L. / Toncheva, D. / Kurteva, G. / Damyanov, D. / Chilingirov, P. et al. | 2015
- i5
-
18P TARTRATE-RESISTANT ACID PHOSPHATASE ISOFORM 5B (TRACP 5B) AS SERUM MARKER OF BONE METASTASES FROM NON-SMALL CELL LUNG CANCER (NSCLC) AND BREAST CANCER. PRELIMINARY RESULTSLumachi, F. / Del Conte, A. / Mazza, F. / Basso, S. M. / Chiara, G. B. et al. | 2015
- i6
-
22PD BODY MASS INDEX AND LUNG CANCER SURVIVAL: RESULTS FROM THE ICARE STUDYSanikini, H. / Clain, G. / Sanchez, M. / Guizard, A. V. / Woronoff, A. S. / Tretarre, B. / Molinie, F. / Delafosse, P. / Luce, D. / St�cker, I. et al. | 2015
- i6
-
20PD PASSIVE SMOKE EXPOSURE IS NOT A SIGNIFICANT RISK FACTOR IN THE DEVELOPMENT OF LUNG CANCERVirdi, R. P. / Fisher, J. M. / Balekian, A. A. et al. | 2015
- i7
-
24PD PREDICTING EARLY LUNG CANCER USING BIG DATAGe, Y. / Ma, L. / Tao, L. W. / Han, M. F. / Ma, L. M. et al. | 2015
- i7
-
26PD THE EFFECT OF EMERGENCY PRESENTATION ON SURGERY AND SURVIVAL IN LUNG CANCER PATIENTS IN ENGLAND, 2006-2008Tataru, D. / Jack, R. H. / M�ller, H. / L�chtenborg, M. et al. | 2015
- i7
-
25P A COMMON BIM DELETION POLYMORPHISM WAS ASSOCIATED WITH THE RISK OF LUNG CANCER IN A CHINESE POPULATIONJing, X. J. et al. | 2015
- i7
-
23PD INTERSTITIAL LUNG DISEASE ON CHEST COMPUTED TOMOGRAPHY IS ASSOCIATED WITH THE DEVELOPMENT OF LUNG CANCERKakal, K. / Fisher, J. M. / Balekian, A. A. et al. | 2015
- i8
-
27P CHARACTERISTICS OF LUNG CANCER DIAGNOSED WITH LOW DOSE CHEST CT SCREENINGChoi, S. / Lee, C. et al. | 2015
- i8
-
28P SEX DIFFERENCES IN PRESENTATION, MANAGEMENT AND PROGNOSIS OF MOROCCAN PATIENTS WITH NON SMALL CELL LUNG CARCINOMA: A RETROSPECTIVE ANALYSIS OF 224 CASESAmaadour, L. / Boudahna, L. / Benbrahim, Z. / Arifi, S. / Mellas, N. et al. | 2015
- i8
-
29P THE RISK OF LUNG CANCER AMONG WOMEN WHO START SMOKING AS TEENAGERSTagbarha, M. O. et al. | 2015
- i8
-
31P PLASMA CRABP2 IN PATIENTS WITH NON-SMALL CELL LUNG CANCERHan, S. S. / Lee, H. Y. / Lee, S. J. / Kim, W. J. / Hong, Y. / Lee, E. J. et al. | 2015
- i8
-
30P THE BELIEFS, ORIENTATION, KNOWLEDGE, UNDERSTANDING, ATTITUDES AND TREATMENT ACCESS TO LUNG CANCER AMONGST RURAL MEN IN NIGERIATagbarha, M. O. et al. | 2015
- i9
-
33P IDIOPATHIC PULMONARY FIBROSIS AS A POOR PROGNOSTIC FACTOR IN LUNG CANCER PATIENTSSon, C. / Um, S. / Roh, M. S. et al. | 2015
- i9
-
32P EPIDEMIOLOGY, TREATMENT PATTERNS AND SURVIVAL OUTCOME IN PATIENTS OF ADVANCED STAGE INOPERABLE LUNG CANCER: A TERTIARY CANCER CARE CENTRE ANALYSISKumar, D. / Pant, M. C. / Singh, S. et al. | 2015
- i10
-
37PD SNPS IN ANGIOGENIC FACTORS AS PREDICTIVE MARKERS FOR OUTCOME IN PATIENTS (P) WITH ADVANCED NON-SQUAMOUS NSCLC (NS-NSCLC) TREATED WITH CARBOPLATIN, PACLITAXEL (CP) AND BEVACIZUMAB (BEV). FINAL RESULTS OF ANGIOMET SPANISH LUNG CANCER GROUP TRIALMassuti Sureda, B. / Jantus-Lewintre, E. / Gonzalez-Larriba, J. L. / Rodriguez Abreu, D. / Juan, O. J. / Domine, M. / Provencio Pulla, M. / de Castro, J. / Camps, C. / Rosell, R. et al. | 2015
- i10
-
36O DETECTION OF EGFR T790M MUTATION IN URINARY CIRCULATING TUMOR DNA FROM METASTATIC NON-SMALL CELL LUNG CANCER PATIENTSHusain, H. / Kosco, K. / Guerrero, S. / Lu, T. T. / Vibat, C. R. / Erlander, M. G. / Melnikova, V. et al. | 2015
- i10
-
38PD CT CHARACTERISTICS ALLOW THE IDENTIFICATION OF PATIENT-SPECIFIC AND REGIONAL SUSCEPTIBILITY FOR RADIATION-INDUCED LUNG DAMAGEDefraene, G. / van Elmpt, W. / Crijns, W. / Slagmolen, P. / De Ruysscher, D. et al. | 2015
- i11
-
42P BIOLOGICAL ROLE OF PROGNOSTIC MICRORNAS (MIRNAS) IN SQUAMOUS LUNG CARCINOMA (SCC) CELLSFilipska, M. / Skrzypski, M. / Stasi?oj?, G. / Bigda, J. et al. | 2015
- i11
-
41P THE COMPARATIVE ESTIMATION OF TUBB3 EXPRESSION IN NON-SMALL-CELL LUNG CARCINOMA AND ADJACENT LUNG TISSUEBogush, T. A. / Mamichev, I. A. / Dudko, E. A. / Grishanina, A. N. / Ramanauskaite, R. J. / Vichljantzeva, N. O. / Tjulandin, S. / Polotsky, B. E. / Davydov, M. I. et al. | 2015
- i11
-
39O IMMUNE CHECKPOINTS SCORE AND CD8+ T CELLS INFILTRATION ARE INDEPENDENT PROGNOSTIC BIOMARKERS IN RESECTED NSCLCUs�, M. / Jantus-Lewintre, E. / Sirera, R. / Calabuig-Fari�as, S. / Blasco, A. / Guijarro, R. / Forteza, J. / Camps, C. et al. | 2015
- i12
-
45P MICRORNA EXPRESSION PROFILING IN LUNG CANCER AND NORMAL TISSUE USING MASSIVELY PARALLEL SEQUENCING TECHNIQUELee, H. Y. / Song, S. Y. / Lim, K. H. / Lee, S. J. / Han, S. S. / Kim, W. J. et al. | 2015
- i12
-
46P ANTITUMOR EFFICACY OF THE DOUBLE SUICIDE GENES IN LUNG CANCER CELLSShen, C. / Che, G. et al. | 2015
- i12
-
44P UPREGULATED MIRNA 21 IN KRAS MUTATED PATIENTS IS RELATED TO PROGNOSIS IN RESECTABLE NON-SMALL CELL LUNG CANCERGallach, S. / Calabuig-Fari�as, S. / Jantus-Lewintre, E. / Montaner, D. / Escorihuela, E. / Blasco, A. / Guijarro, R. / Camps, C. et al. | 2015
- i12
-
43P MIR31-3P EXPRESSION IN PATIENTS WITH ADVANCED LEPIDIC ADENOCARCINOMA (L-ADC) TREATED WITH EGFR TKI IN IFCT 0401 AND 0504 TRIALSThiebaut, R. / Wislez, M. / Vazart, C. / Decaulne, V. / Mazieres, J. / Friard, S. / Merle, P. / Morin, F. / Liebaert, F. / Cadranel, J. et al. | 2015
- i13
-
48P DEVELOPMENT OF RESISTANCE MODELS TO TYROSINE KINASE INHIBITORS (TKIS) IN PATIENT-DERIVED XENOGRAFT MODELS (PDXS) OF LUNG ADENOCARCINOMA WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONSStewart, E. L. / Sakashita, S. / Wang, T. / Pham, N. A. / Li, M. / Liu, G. / Tsao, M. S. et al. | 2015
- i13
-
49P SYNERGISTIC EFFECT OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR IN EGFR-TKI RESISTANT NON-SMALL CELL LUNG CANCER CELL LINESHan, X. / Zhang, N. / Yao, J. / Shi, Y. et al. | 2015
- i13
-
47P PHARMACOGENETICS & TREATMENT OUTCOME IN CANCER PATIENTS RECEIVING RADIO-CHEMOTHERAPYYadav, S. S. / Chauhan, V. / Parmar, D. et al. | 2015
- i14
-
52P MULTIPARAMETER PLOIDY PROFILING: A POWERFUL TOOL TO INVESTIGATE THE GENOMICS OF DIPLOID TUMOR POPULATIONSLorber, T. / Rau, S. / Perrina, V. / Barrett, M. / Ruiz, C. / Bubendorf, L. et al. | 2015
- i14
-
50P ENUMERATION AND MOLECULAR CHARACTERIZATION OF CIRCULATING TUMOR CELLS IN LUNG CANCER PATIENTS USING THE GILUPI CELLCOLLECTOR, AN EFFECTIVE IN VIVO DEVICE FOR CAPTURING CTCSScheumann, N. / Gorges, T. / Penkalla, N. / Nowack, B. / Schalk, T. / Riethdorf, S. / L�cke, K. / Pantel, K. / Krahn, T. / Schumann, C. et al. | 2015
- i14
-
51P GEF GENE: A NEW SUICIDE GENE THERAPY FOR NON-SMALL CELL LUNG CANCERRama Ballesteros, A. R. / Hern�ndez, R. / Perazzoli, G. / Oliver, J. / Cabeza, L. / Jim�nez-Luna, C. / Leiva, M. C. / Jim�nez, J. / Prados, J. et al. | 2015
- i15
-
53O IS ROUTINE SAMPLING OF THE INFERIOR MEDIASTINAL LYMPH NODE STATIONS A NECESSITY FOR PRE-OPERATIVE MEDIASTINAL STAGING IN LUNG CANCER? RESULTS OF A LARGE RETROSPECTIVE STUDY OF 986 SURGICAL RESECTIONSEvison, M. / Britton, S. / Al-Najjar, H. / Crosbie, P. / Bishop, P. / Jones, M. / Krysiak, P. / Rammohan, K. / Shah, R. / Booton, R. et al. | 2015
- i15
-
54PD ADVANTAGES OF DIFFUSION WEIGHTED IMAGING OF PULMONARY NODULES AND MASSES: COMPARISON WITH POSITRON EMISSION TOMOGRAPHYUsuda, K. / Sagawa, M. / Motono, N. / Ueno, M. / Tanaka, M. / Machida, Y. / Maeda, S. / Matoba, M. / Tonami, H. / Ueda, Y. et al. | 2015
- i15
-
55P PROPOSED NEW SIMPLE CRITERIA OF CLINICAL MULTIPLE PRIMARY LUNG CANCERSMatsunaga, T. / Suzuki, K. / Takamochi, K. / Oh, S. et al. | 2015
- i15
-
56P FDG PET/CT FOR EVALUATION OF MEDIASTINAL LYMPH NODE STAGING USING FDG UPTAKE AND VOLUMETRIC CT HISTOGRAM IN NON-SMALL CELL LUNG CANCERLee, J. W. / Lee, S. M. / Lee, J. H. et al. | 2015
- i17
-
57P INHIBITION OF THE FOCAL ADHESION KINASE HAS ANTI-TUMORAL EFFECT IN SMALL-CELL LUNG CANCER CELL LINESAboubakar, F. / Lecocq, M. / Detry, B. / Maha, L. / Massion, P. P. / Sibille, Y. / Pilette, C. / Ocak, S. et al. | 2015
- i17
-
58P RADIATION THERAPY (RT) IN THE PALLIATIVE TREATMENT OF METASTATIC SMALL CELL LUNG CANCER (SCLC)Ragulin, Y. / Ivanova, I. / Gulidov, I. / Mardynsky, Y. / Zolotkov, A. / Gogolin, D. / Kursova, L. et al. | 2015
- i18
-
61O OUTCOME OF SURGICAL SALVAGE FOR LOCAL FAILURES FOLLOWING STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)Verstegen, N. E. / Lagerwaard, F. J. / Paul, M. A. / Smit, E. F. / Versteegh, M. I. / Joosten, J. J. / Slotman, B. J. / Senan, S. et al. | 2015
- i18
-
62O THIRTY AND 90-DAY MORTALITY AFTER LUNG CANCER RESECTION IN 2242 PATIENTSFrick, A. E. / L�ders, H. / Leschber, G. et al. | 2015
- i18
-
60O ANALYSIS OF LOCAL RECURRENCES FOLLOWING STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR): DATA FROM A LARGE INSTITUTIONAL DATABASEVerstegen, N. E. / Lagerwaard, F. J. / Slotman, B. J. / Dahele, M. / Senan, S. et al. | 2015
- i19
-
66P PROGNOSTIC CLASSIFICATION OF LUNG ADENOCARCINOMA BY INTEGRATED MIRNA-MRNA EXPRESSION PROFILESTam, S. / Pintilie, M. / Liu, N. / McPherson, J. D. / Tsao, M. S. et al. | 2015
- i19
-
63PD COMPARISON OF CLINICAL OUTCOME OF STAGE I NON-SMALL CELL LUNG CANCER TREATED SURGICALLY OR WITH STEREOTACTIC RADIOTHERAPY: RESULTS FROM PROPENSITY SCORE ANALYSISMokhles, S. / Verstegen, N. E. / Maat, A. P. / Birim, O. / Bogers, A. J. / Mokhles, M. M. / Lagerwaard, F. J. / Senan, S. / Takkenberg, J. J. et al. | 2015
- i19
-
65PD PROGNOSTIC INFLUENCE OF MUTATIONAL STATUS IN RESECTED NON-SMALL CELL LUNG CANCER: THE KRAS G12V WORSE VALUERenaud, S. / Falcoz, P. E. / Schaeffer, M. / Beau-Faller, M. / Romain, B. / Olland, A. / Reeb, J. / Santelmo, N. / Massard, G. / Voegeli, A. C. et al. | 2015
- i19
-
64PD EFFECT OF COMORBIDITY ON SURGERY AND SURVIVAL AMONG LUNG CANCER PATIENTS IN ENGLANDL�chtenborg, M. / Riaz, S. P. / Jack, R. H. / Peake, M. D. / Lind, M. J. / M�ller, H. et al. | 2015
- i20
-
67P MRNA EXPRESSION LEVEL OF LYMPHANGIOGENESIS-ASSOCIATED GENES IN EARLY-STAGE NON-SMALL CEL LUNG CANCERKowalczuk, O. / Kozlowski, M. / Laudanski, W. / Kisluk, J. / Niklinski, J. et al. | 2015
- i20
-
68P THE UTILITY OF ACTININ-4 PROTEIN OVEREXPRESSION AS A PREDICTIVE BIOMARKER FOR THERAPEUTIC EFFECT OF ADJUVANT CHEMOTHERAPY TO THE RESECTED LUNG ADENOCARCINOMAShiraishi, H. / Fujiwara, Y. / Kakuya, T. / Tsuta, K. / Watanabe, S. / Huang, W. / Yamada, T. / Asamura, H. / Ohe, Y. / Honda, K. et al. | 2015
- i20
-
69P THE IMPACT OF GENETIC ALTERATION ON RECURRENCE IN PATIENTS WITH RESECTED STAGE I NON-SMALL CELL LUNG CANCERChung, H. S. / Heo, E. Y. / Park, S. S. / Park, Y. S. / Kim, Y. W. / Kim, D. K. et al. | 2015
- i20
-
70P PROGNOSTIC ROLE OF T-REGULATORY CELLS IN COMPLETELY RESECTED EARLY STAGE NON-SMALL CELL LUNG CARCINOMAKose, F. / Abali, H. / F?nd?kc?oglu, A. / Canpolat, T. / Besen, A. A. / Sumbul, A. T. / Mertsoylu, H. / Sedef, A. M. / Ozyilkan, O. et al. | 2015
- i21
-
73P OUTCOME OF EARLY-STAGE LUNG CANCER TREATED WITH STEREOTACTIC BODY RADIOTHERAPY (SBRT)Alameddine, M. / Chan, J. / Pope, A. / Haridass, A. / Baker, A. / Meara, S. / Clements, R. / Crabtree, A. / Wong, H. / Eswar, C. et al. | 2015
- i21
-
74P DOES A HIGHER SURGICAL RESECTION RATE IN LUNG CANCER LEAD TO A HIGHER RATE OF POST-OPERATIVE MULTI-STATION N2 DISEASE?Evison, M. / Britton, S. / Al-Najjar, H. / Crosbie, P. / Bishop, P. / Jones, M. / Krysiak, P. / Rammohan, K. / Shah, R. / Booton, R. et al. | 2015
- i21
-
72P OCCURRENCE OF SIGNIFICANT TUMOR VOLUME CHANGES DURING STEREOTACTIC BODY RADIATION THERAPY FOR LUNG CANCERCharlier, F. / Moretti, L. / Jourani, Y. / de Brouwer, T. / Van Houtte, P. et al. | 2015
- i21
-
71P OUTCOME AFTER SBRT FOR POTENTIALLY OPERABLE NSCLC PATIENTSRossi, M. / Peulen, H. / van Tinteren, H. / Wouters, M. / Sonke, J. J. / Baas, P. / Smit, E. F. / Belderbos, J. et al. | 2015
- i22
-
76P RESULT OF THE 6-MINUTE WALK TEST IS AN INDEPENDENT PROGNOSTIC FACTOR OF SURGICALLY TREATED NON-SMALL CELL LUNG CANCERMarjanski, T. / Badocha, M. / Wnuk, D. / Mosiewicz, A. / Rzyman, W. et al. | 2015
- i22
-
78P EXAMINATION OF PROGNOSTIC FACTORS IN CASES RECEIVING UFT AS POSTOPERATIVE ADJUVANT CHEMOTHERAPY FOR LUNG CANCERNawa, K. / Yoneyama, R. / Kakihana, M. / Kajiwara, N. / Ohira, T. / Ikeda, N. et al. | 2015
- i22
-
75P ADEQUACY OF LYMPH NODE SAMPLING DURING SURGICAL RESECTION OF LUNG CANCER AT A REGIONAL UK THORACIC SURGICAL CENTRE 2011-2013Evison, M. / Britton, S. / Al-Najjar, H. / Crosbie, P. / Jones, M. / Bishop, P. / Krysiak, P. / Rammohan, K. / Shah, R. / Booton, R. et al. | 2015
- i22
-
77P POST-OPERATIVE OUTCOMES IN NON-SMALL CELL LUNG CANCER PATIENTS WITH MILD TO MODERATE STAGE CHRONIC OBSTRUCTIVE PULMONARY DISEASEItotani, R. / Marumo, S. / Kumagai, S. / Yamanashi, K. / Tokuno, J. / Sumitomo, R. / Shoji, T. / Huang, C. / Fukui, M. et al. | 2015
- i23
-
79P VOLUME CHANGES WITH HYPO-FRACTIONATED RADIOTHERAPY IN EARLY LUNG CANCER: TIME TRENDS & OUTCOMESPathak, R. S. / Tibdewal, A. R. / Ghosh Laskar, S. / Chaudhari, S. / Agarwal, J. P. et al. | 2015
- i23
-
80P ROLE OF TREATMENT IN INTERNATIONAL DIFFERENCES IN ONE-YEAR MORTALITY FROM EARLY STAGE NON-SMALL CELL LUNG CANCER: A TENTATIVE ANSWER FROM THE INTERNATIONAL CANCER BENCHMARKING PARTNERSHIP STUDYSolomon, T. / Peake, M. D. / Butler, J. / Coleman, M. P. / Evans, W. K. / Jakobsen, E. / Boyer, M. / Johannesen, T. B. / Rachet, B. et al. | 2015
- i24
-
83PD PROGNOSIS OF STAGE III NON-SMALL-CELL LUNG CANCER PATIENTS PRESENTING WITH ISOLATED BRAIN FAILURE AFTER DEFINITIVE CONCURRENT CHEMORADIATION THERAPYTopkan, E. / Guler, O. C. / Yildirim, B. A. et al. | 2015
- i24
-
81O ERLOTINIB AS NEOADJUVANT TREATMENT IN ENDOBRONCHIAL ULTRASOUND CONFIRMED STAGE IIIA-N2 NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION (EXON 19 OR 21) (NCT01217619, ESTERN): A PROSPECTIVE, SINGLE ARM, PHASE II CLINICAL TRIALHan, B. / Xiong, L. / Sun, J. / Li, R. / Lou, Y. / Zhang, Y. / Gu, A. / Jiang, L. / Shi, J. et al. | 2015
- i24
-
82PD THE VOLUME MATTERS IN STAGE III NSCLC PATIENTS TREATED WITH CONCURRENT CHEMORADIOTHERAPYvan Diessen, J. / Chen, C. / Heemsbergen, W. / van den Heuvel, M. / Belderbos, J. / Sonke, J. J. et al. | 2015
- i25
-
84P TRIMODALITY THERAPY INCLUDING RADICAL RESECTION FOR PANCOAST TUMORS: T4 IS NOT A CONTRAINDICATION FOR RADICAL SURGERYHoda, M. A. / Waseda, R. / Klikovits, T. / Foesleitner, O. / Zoechbauer-Mueller, S. / Dieckmann, K. / Prosch, H. / Pirker, R. / Klepetko, W. et al. | 2015
- i25
-
85P REVIEW OF RADICAL RADIOTHERAPY +/- CHEMOTHERAPY FOR STAGE III NSCLCButton, M. / Evans, R. / Rees, E. M. / Bullock, C. et al. | 2015
- i25
-
86P CAN CONCURRENT CHEMO-RADIATION BE DELAYED BY INDUCTION CHEMOTHERAPY IN THE CURATIVE TREATMENT OF STAGE III NON-SMALL CELL LUNG CARCINOMA? A POOLED ANALYSISGuilbault, C. / Garant, A. / Almajed, M. / Faria, S. / Owen, S. / Duclos, M. / Ofiara, L. / Gruber, J. / Hirsh, V. / Kopek, N. et al. | 2015
- i26
-
88P OMISSION OF ELECTIVE NODAL IRRADIATION HAS NO IMPACT ON ISOLATED ELECTIVE NODAL FAILURE AND SURVIVAL OUTCOMES IN STAGE III NON-SMALL-CELL LUNG CANCER PATIENTS TREATED WITH DEFINITIVE CONCURRENT CHEMORADIOTHERAPYTopkan, E. / Guler, O. C. / Yildirim, B. A. et al. | 2015
- i26
-
87P WHAT TO DO FOR THE TREATMENT OF NON SMALL CELL LUNG CANCER (NSCLC) WITH A SINGLE MEDIASTINAL LYMPH NODE INVOLVEMENT (N2A DISEASE) IN DEVELOPING COUNTRIES?Caushi, F. / Hafizi, H. / Mezini, A. / Xhemalaj, D. / Skenduli, I. et al. | 2015
- i26
-
90P CONCURRENT CHEMORADIOTHERAPY WITH VINORELBINE PLUS SPLIT-DOSE CISPLATIN IN INOPERABLE STAGE III NON-SMALL CELL LUNG CANCERMertsoylu, H. / Kose, F. / Sedef, A. M. / Dogan, O. / Parlak, C. / Besen, A. A. / Sumbul, A. T. / F?nd?kc?oglu, A. / Sezer, A. / Muallaoglu, S. et al. | 2015
- i26
-
89P CLINICAL FACTORS OF NODAL UPSTAGING IN PATHOLOGIC N1 OR N2 NON-SMALL CELL LUNG CANCERMoon, Y. / Sung, S. W. / Kim, K. S. / Park, J. K. et al. | 2015
- i27
-
91P DEFINITIVE CONCOMITANT RADIOCHEMOTHERAPY (RCT) TREATMENT FOR LOCALLY ADVANCED (LA) NON SMALL CELL LUNG CANCER (NSCLC): EVALUATION OF HEMATOLOGICAL AND ESOPHAGEAL TOXICITY IN THE RADIATION ONCOLOGY DEPARTMENT OF UNIVERSITY OF FLORENCE EXPERIENCEScotti, V. / Scartoni, D. / Furfaro, I. F. / Simontacchi, G. / De Luca Cardillo, C. / Agresti, B. / Talamonti, C. / Livi, L. et al. | 2015
- i27
-
94P LUNG CANCER IN WOMEN, A DIFFERENT DISEASE: SURVIVAL DIFFERENCES BY SEXUlas, A. / Tokluoglu, S. T. / K�s, M. / Silay, K. / Akinci, S. / Oksuzoglu, B. O. / Alkis, N. et al. | 2015
- i27
-
93P THE CLINICAL CHARACTERISTICS OF 50 PATIENTS WITH RADIATION PNEUMONITISLiu, R. / Zhang, Q. / Wang, X. et al. | 2015
- i27
-
92P SOCIAL DEPRIVATION AND RADICAL TREATMENT OF STAGE III NSCLCButton, M. / Evans, R. / Bullock, C. / Rees, E. M. et al. | 2015
- i28
-
95TiP A PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL STUDY OF MEDI4736 IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE, STAGE 3 NSCLC WHO HAVE NOT PROGRESSED FOLLOWING PLATINUM-BASED, CONCURRENT CHEMORADIATION THERAPY (PACIFIC)Creelan, B. / Iannotti, N. O. / Salamat, M. A. / Jayawardene, D. / Ballas, M. / Stockman, P. K. / Antonia, S. J. et al. | 2015
- i29
-
96O DETERMINING THE PREVALENCE OF EGFR MUTATIONS IN ASIAN AND RUSSIAN PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (ANSCLC) OF ADENOCARCINOMA (ADC) AND NON-ADC HISTOLOGY: IGNITE STUDYHan, B. / Tjulandin, S. / Hagiwara, K. / Normanno, N. / Wulandari, L. / Konstantin Konstantinovich, L. / Hudoyo, A. / Ratcliffe, M. / McCormack, R. / Reck, M. et al. | 2015
- i30
-
97O EGFR MUTANT SUBSET ANALYSIS FROM ARCHER 1009: A RANDOMIZED DOUBLE BLIND PHASE 3 EFFICACY AND SAFETY STUDY OF DACOMITINIB VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)Paz-Ares, L. / O'Byrne, K. / Mok, T. S. / Boyer, M. / J�nne, P. A. / Goldberg, Z. / Mather, C. / Taylor, I. / Zhang, H. / Ramalingam, S. S. et al. | 2015
- i30
-
99O PHASE 1/2 STUDY OF AP26113 IN PATIENTS (PTS) WITH ADVANCED MALIGNANCIES, INCLUDING ANAPLASTIC LYMPHOMA KINASE (ALK)POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC): ANALYSIS OF SAFETY AND EFFICACY AT SELECTED PHASE 2 DOSESRosell, R. / Gettinger, S. / Bazhenova, L. A. / Langer, C. J. / Salgia, R. / Gold, K. / Shaw, A. T. / Dorer, D. J. / Kerstein, D. / Camidge, D. R. et al. | 2015
- i31
-
101PD A PROSPECTIVE RANDOMIZED OPEN LABEL PHASE III STUDY OF GEFTINIB VERSUS DOCETAXEL AS SECOND OR THIRD LINE THERAPY IN PATIENTS WITH ADVANCED NON SMALL CELL LUNG CANCER IN ASIAN INDIANSKapoor, A. / Kumar, N. / Narayan, S. / Nirban, R. K. / Maharia, S. / Beniwal, S. K. / Jakhar, S. L. / Kumar, H. S. et al. | 2015
- i31
-
100PD A PROSPECTIVE RANDOMIZED OPEN LABEL PHASE III STUDY OF MAINTENANCE GEMCITABINE VERSUS BEST SUPPORTIVE CARE FOLLOWING PLATINUM-PACLITAXEL CHEMOTHERAPY FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCERJakhar, S. L. / Narayan, S. / Kapoor, A. / Beniwal, S. K. / Singhal, M. K. / Kumari, P. / Singh, G. / Kumari, S. / Kumar, H. S. / Bardia, M. R. et al. | 2015
- i31
-
102PD A RANDOMIZED, DOUBLE-BLIND, PHASE 2 TRIAL OF VELIPARIB (ABT-888) WITH CARBOPLATIN AND PACLITAXEL IN PREVIOUSLY UNTREATED METASTATIC OR ADVANCED NON-SMALL CELL LUNG CANCERMazieres, J. / Blais, N. / Juhasz, E. / Urban, L. / Orlov, S. / Qin, Q. / McKee, M. / Giranda, V. / Gorbunova, V. / Ramalingam, S. S. et al. | 2015
- i32
-
103PD SUBGROUP ANALYSIS OF ELDERLY PATIENTS IN SQUIRE: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III STUDY OF NECITUMUMAB (N) PLUS GEMCITABINE-CISPLATIN (GC) CHEMOTHERAPY VERSUS GC ALONE IN FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER (SQ-NSCLC)Thatcher, N. / Ciuleanu, T. E. / Ramlau, R. / Schumann, C. / Paz-Ares, L. / Depenbrock, H. / Nanda, S. / Chouaki, N. / Socinski, M. et al. | 2015
- i32
-
104PD PHASE 2 STUDY OF NIVOLUMAB (ANTI-PROGRAMMED DEATH-1 [PD-1]) IN PATIENTS (PTS) WITH ADVANCED, REFRACTORY SQUAMOUS (SQ) NON-SMALL CELL LUNG CANCER (NSCLC)Zalcman, G. / Rizvi, N. A. / Lena, H. / Wolf, J. / Mazieres, J. / Antonia, S. J. / Minenza, E. / Planchard, D. / Lestini, B. J. / Ramalingam, S. S. et al. | 2015
- i33
-
106PD EGFR MUTATION DETECTION IN PLASMA OF LUNG TUMOR PATIENTS IN THE ABSENCE OF CONTRIBUTIVE TISSUE IS A RELEVANT ALTERNATIVE FOR PRESCRIPTION OF TYROSINE KINASE INHIBITORS IN A ROUTINE CLINICAL SETTINGDenis, M. G. / Masson, P. / Vall�e, A. / Pigeanne, T. / Lacroix, H. et al. | 2015
- i33
-
107PD AFATINIB (A) PLUS PACLITAXEL (P) FOLLOWING PROGRESSION ON A MONOTHERAPY IN PATIENTS (PTS) WITH METASTATIC NONSMALL-CELL LUNG CANCER (NSCLC) WHO PREVIOUSLY BENEFITED FROM ERLOTINIB (E)/GEFITINIB (G): A GLOBAL RANDOMISED PHASE III TRIALLUX-LUNG 5 (LL5)Schuler, M. / Yang, J. C. / Park, K. / Chand, V. K. / Wang, B. / Planchard, D. et al. | 2015
- i33
-
105PD TG4010 IMMUNOTHERAPY COMBINED WITH FIRST-LINE CHEMOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC). PHASE 2B RESULTS OF THE TIME STUDYQuoix, E. / Nemunaitis, J. / Papai, Z. / Lena, H. / Genet, D. / Louis, C. / Cobo, M. / Al Farhat, Y. / Marie-Bastien, B. / Limacher, J. M. et al. | 2015
- i34
-
108PD AFATINIB (A) VS ERLOTINIB (E) AS SECOND-LINE TREATMENT OF PATIENTS (PTS) WITH ADVANCED SQUAMOUS CELL CARCINOMA (SCC) OF THE LUNG FOLLOWING FIRST-LINE PLATINUM-BASED CHEMOTHERAPY: LUX-LUNG 8 (LL8), A PHASE III GLOBAL TRIALGoss, G. D. / Felip, E. / Cobo, M. / Lu, S. / Georgoulias, V. / Ardizzoni, A. / Gadgeel, S. / Wang, B. / Chand, V. K. / Soria, J. C. et al. | 2015
- i34
-
109PD OVERALL SURVIVAL (OS) WITH AFATINIB (A) VS CHEMOTHERAPY (CT) IN PATIENTS (PTS) WITH NSCLC HARBOURING EGFR MUTATIONS (MUT): SUBGROUP ANALYSES BY RACE IN LUX-LUNG 3 (LL3) AND LUX-LUNG 6 (LL6)Schuler, M. / Yang, J. C. / Sequist, L. V. / Yamamoto, N. / Zhou, C. / Hu, C. P. / O'Byrne, K. / Hirsh, V. / Mok, T. S. / Wu, Y. L. et al. | 2015
- i35
-
110PD SINGLE ORGAN METASTATIC DISEASE, A NEW PROGNOSTIC FACTOR FOR OVERALL SURVIVAL (OS) IN STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC)Hendriks, L. / Derks, J. L. / Postmus, P. E. / Damhuis, R. A. / Houben, R. M. / Troost, E. G. / Hochstenbag, M. M. / Smit, E. F. / Dingemans, A. M. et al. | 2015
- i35
-
112P EFFICACY AND SAFETY OF IMPRIME PGG, A NOVEL INNATE IMMUNE MODULATOR, IN COMBINATION WITH BEVACIZUMAB (BEV), CARBOPLATIN AND PACLITAXEL FOR THE 1ST-LINE TREATMENT OF STAGE IV NSCLCBraun, A. / Engel-Riedel, W. / Schneller, F. / Wolf, M. / Schuette, W. / Lowe, J. / Mattson, P. / Gargano, M. / Patchen, M. / Huhn, R. et al. | 2015
- i35
-
111P CERITINIB TREATMENT OF PATIENTS (PTS) WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES: ASCEND-1 TRIAL EXPERIENCEKim, D. W. / Mehra, R. / Tan, D. / Felip, E. / Szczudlo, T. / Rodriguez Lorenc, K. / Sutradhar, S. / Shaw, A. T. et al. | 2015
- i36
-
114P A PHASE 1B STUDY OF ANTI-DLL4 (DELTA-LIKE LIGAND 4) ANTIBODY DEMCIZUMAB (DEM) WITH PEMETREXED (PEM) AND CARBOPLATIN (CARBO) IN PATIENTS WITH 1ST-LINE NON-SQUAMOUS NSCLCDupont, J. / McKeage, M. / Kotasek, D. / Markman, B. / Hidalgo, M. / Millward, M. / Jameson, M. / Harris, D. / Stagg, R. / Hughes, B. et al. | 2015
- i36
-
116P CLINICAL CHARACTERISTICS AND RESPONSE TO EGFR TKI IN NEVER SMOKER SQUAMOUS LUNG CANCEREe, S. / Young, S. / Tan, E. H. / Lim, D. / Tan, G. S. / Jain, A. / Zeng, W. / Lim, T. / Takano, A. / Tan, D. et al. | 2015
- i36
-
113P ANLOTINIB AS THIRD-LINE TREATMENT IN PATIENTS WITH REFRACTORY ADVANCED NON-SMALL CELL LUNG CANCER: A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II TRIAL (NCT01924195)Han, B. / Li, K. / Zhao, Y. / Li, B. / Cheng, Y. / Zhou, J. / Lu, Y. / Shi, Y. / Wang, Z. / Jiang, L. et al. | 2015
- i36
-
115P KIF5B & CCDC6 RET IN LUNG CANCER: CLINICAL INSIGHTS AND RESPONSE TO PERSONALIZED BASED THERAPYSarfaty, M. / Moore, A. / Gottfried, M. / Katznelson, R. / Nechushtan, H. / Wolner, M. / Neiman, V. / Soussan-Gutman, L. / Dvir, A. / Peled, N. et al. | 2015
- i37
-
117P GERMAN COUNTRY-WIDE SURVEYS FROM 2012 AND 2014 ABOUT EGFR MUTATIONAL TESTING ALGORITHMS ADOPTED BY MEDICAL DOCTORS IN PATIENTS WITH NSCLCOstermann, H. / Ukena, D. / Radke, S. / Freitag, A. / H�rnig, S. et al. | 2015
- i37
-
118P ERLOTINIB AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED EGFR MUTATION-POSITIVE NON-SMALL-CELL LUNG CANCER: PHASE IIIB STUDYZaric, B. / Perin, B. / Cekic, M. / Rancic, M. / Kovcin, V. / Andric, Z. / Murtezani, Z. H. / Jovanovic, D. / Velinovic, M. / Markovic, M. et al. | 2015
- i37
-
119P REVERSIBLE VERSUS IRREVERSIBLE EGFR TYROSINE-KINASE INHIBITORS FOR NON-SMALL-CELL LUNG CANCER (NSCLC): A PRECLINICAL AND PHARMACOKINETIC COMPARISONLiederer, B. M. / Friess, T. / Shames, D. / Wright, M. / Hop, C. E. et al. | 2015
- i38
-
122P ICOTINIB AS FIRST-LINE TREATMENT FOR ELDERLY PATIENTS WITH EGFR 19 OR 21 MUTATION IN ADVANCED NSCLC: A PHASE-IV, OPEN-LABEL, SINGLE-ARM STUDYHan, B. / Shi, C. / Qian, J. / Li, R. et al. | 2015
- i38
-
123P OUTCOMES OF OCTOGENARIAN (?80 YO) PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A SINGLE INSTITUTION EXPERIENCE FROM THE CHRISTIE HOSPITALHowell, M. / Chiramel, J. / Flaum, N. / Lewis, A. / Summers, Y. / Taylor, P. / Chittalia, A. / Sheikh, H. / Blackhall, F. H. et al. | 2015
- i38
-
121P SERUM CARCINOEMBRYONIC ANTIGEN LEVELS PREDICTS THE EFFICACY OF EGFR-TKI IN NON-SMALL CELL LUNG CANCER HARBORING EGFR MUTATIONSZhang, Y. / Han, B. / Jin, B. / Lou, Y. / Li, R. / Zhang, X. / Hu, S. et al. | 2015
- i38
-
124P PLATINUM BASED CHEMOTHERAPY FOR THE TREATMENT OF ELDERLY PATIENTS WITH METASTATIC NON SMALL CELL LUNG CARCINOMA: A RETROSPECTIVE ANALYSIS OF A SINGLE INSTITUTIONAmaadour, L. / Boudahna, L. / Benbrahim, Z. / Arifi, S. / Mellas, N. et al. | 2015
- i38
-
120P IS SWITCH MAINTENANCE THERAPY MANDATORY FOR EGFR MUTATED PATIENTS INITIATED ON CHEMOTHERAPY?Roy, R. et al. | 2015
- i39
-
126P OUTCOMES OVER A DECADE IN STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC): THE CLATTERBRIDGE CANCER CENTRE EXPERIENCEEscriu, C. / Wong, H. / Marshall, E. et al. | 2015
- i39
-
127P A PROSPECTIVE RANDOMIZED PHASE III STUDY EVALUATING QUALITY OF LIFE IN ADVANCED NON-SMALL CELL LUNG CANCER RECEIVING PLATINUM BASED CHEMOTHERAPY COMBINATION IN OLD VERSUS NEW STANDARD CHEMOTHERAPY REGIMENRungta, A. / Kapoor, A. / Dutta, S. et al. | 2015
- i39
-
128P COMPARISON OF EFFICACY OF PEMETREXED PLUS PLATINUM AND NON-PEMETREXED PLUS PLATINUM AS 1ST LINE CHEMOTHERAPY IN EGFR WILD TYPE NON-SQUAMOUS NSCLCKang, E. J. / Lee, S. Y. / Kim, J. S. et al. | 2015
- i39
-
125P A PROSPECTIVE RANDOMIZED PHASE III STUDY OF PALLIATIVE CHEMOTHERAPY VERSUS BEST SUPPORTIVE CARE IN ELDERLY PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER: SURVIVAL ANALYSIS AND ECOG PERFORMANCE STATUS REGRESSION ANALYSISKumar, N. / Kapoor, A. / Kalwar, A. / Narayan, S. / Singhal, M. K. / Kumar, A. / Lal, S. / Nirban, R. K. / Paramanandhan, M. / Purohit, R. et al. | 2015
- i40
-
132P WEEKLY CARBOPLATIN AND PACLITAXEL IN ADVANCED NON-SMALL CELL LUNG CANCER: GOOD RESPONSE RATE BUT POOR OVERALL SURVIVAL IN A REAL WORLD POPULATIONMark, M. / Volk, V. / Mey, U. / Brossart, P. / von Moos, R. / Cathomas, R. et al. | 2015
- i40
-
131P DURATION AND TOLERANCE OF MAINTENANCE PEMETREXED (MPEM) TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCERCharlton, P. / Josephides, E. / Karapanagiotou, E. / Montes, A. / Spicer, J. / Lal, R. et al. | 2015
- i40
-
130P MAINTENANCE PEMETEREXED IN NSCLC - OUTCOME ANALYSIS FROM A TERTIARY CARE CENTERPandey, A. V. / Prabhash, K. / Noronha, V. / Joshi, A. et al. | 2015
- i40
-
129P EFFECTIVENESS OF FIRST-LINE PEMETREXED PLUS PLATINUM FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCERBrand�o, M. D. / Luis, M. S. / Amaral, N. C. / Cassiano Neves, M. / Camacho, C. / Rodrigues, A. C. / Pousa, I. / Oliveira, J. / Azevedo, I. et al. | 2015
- i41
-
136P TTF1 EXPRESSION IN ADVANCED NON-SMALL CELL LUNG CANCER: IMPACT ON SURVIVAL OUTCOMEElsamany, S. / Al-fayea, T. / Abozeed, W. N. / Alzahrani, A. / Farooq, M. U. / Darwish, W. / Almadani, A. / Bukhari, E. et al. | 2015
- i41
-
134P EFFECT OF HAEMATOLOGICAL ADVERSE EFFECTS OCCURING DURING CHEMOTHERAPY ON RESPONSE TO TREATMENT AND PROGRESSION FREE SURVIVAL IN ADVANCED NSCLCNagy, A. A. / Fouad, E. / Nasr, K. / El-Ghazaly, H. / Adel, A. et al. | 2015
- i41
-
133P AN ESTIMATION OF THE POPULATION-BASED SURVIVAL BENEFIT OF FIRST-LINE CHEMOTHERAPY FOR LUNG CANCERDo, V. / Ng, W. / Jacob, S. / Delaney, G. / Barton, M. et al. | 2015